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Years of preparations. 
Months of waiting. 
Days to remember. 
Hours until sunrise. 
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Seconds of glory. 
Big time is here. 
 
David Carson 
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1.2 Abbreviations 
 
ATCC  American Type Culture Collection 
ATM  ataxia telangiectasia mutated 
5-FU  5-fluorouracil 
APR  abdominoperineal resection 
CI  combination index 
CDK  cyclin dependent kinase 
CRM  circumferential resection margin 
CRT  chemoradiotherapy 
CT  computerized tomography 
DMSO  dimethyl sulfoxide 
dsb  double strand break 
DW-MRI diffusion weighted magnetic resonance imaging 
Gy  Gray, unit for radiation dose 
HE  hematoxylin-eosin 
EGFR  epidermal growth factor receptor 
FITC  fluorescein isothiocyanate 
HAT  histone acetyl transferase 
HDAC  histone deacetylase 
IHC  immunohistochemistry 
HR  homologous recombination 
IORT  intraoperative radiotherapy 
IR  ionizing radiation 
ip  intraperitoneal 
iv  intravenous 
LAR  low anterior resection 
LARC  locally advanced rectal cancer 
LARC-RRP locally advanced rectal cancer – radiation response prediction 
LOOCV leave one out cross validation 
MRI  magnetic resonance imaging 
MRS  magnetic resonance spectroscopy 
NACT  neoadjuvant chemotherapy 
NHEJ  non-homologous endjoining 
pCR  pathological complete response 
PLS  partial least squares 
RT  radiotherapy 
SAHA  suberoylanilide hydroxamic acid 
sc  subcutaneous 
ssb  single strand break 
TNM  tumor, node, metastasis 
TRG  tumor regression grade 
TSA  trichostatin A 
VEGF  vascular endothelial growth factor 
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2 General introduction 
 
2.1 Rectal cancer 
 
2.1.1 Epidemiology 
Colorectal cancer is the third most frequent cancer in both genders combined, after prostate and 
breast cancer. Around 30 % of all colorectal cancer cases are diagnosed in the rectal anatomical 
site, defined as tumors with the inferior margin within 16 cm from the anal verge as assessed by 
rigid rectoscopy. In 2007, 1111 new cases of rectal cancer were diagnosed in Norway with an 
age-adjusted (world) incidence rate per 100 000 persons-years of 15.4 and 10.7 for men and 
women, respectively (1). The incidence rates have been stable over the last ~20 years (Figure 
1), however, due to an aging population and increased survival after treatment, the prevalence 
has increased from 6883 on the 31st December 1997 to 9259 persons on the 31st December 2007 
(1). The incidence rates in Norway are among the highest in the world (2, 3), but the survival 
rates are also among the highest (4, 5). Five-year survival of persons diagnosed during 1998-
2002 was 58.2% and 63.8% for men and women, respectively, an increase from 1978-1982 
which was 44.2% and 47.4% (1). The increased survival rates may be attributed to advances in 
surgical techniques, centralized surgery, more effective (neo-)adjuvant oncologic treatment, as 
well as improved general patient care reducing treatment complications. 
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Figure 1: Trends in age-standardised 5-year survival proportions and incidence and mortality 
rates for rectal cancer 1965-2007. With permission from the Cancer Registry of Norway, 2009 
(6). 
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2.1.2 Risk factors and prevention 
Risk factors for rectal cancer are mainly similar to those of colon cancer, with a few exceptions. 
Dietary factors that are associated with increased risk include high intake of red and processed 
meat and alcohol consumption of more than 30 g/day. High dietary intake of fish, calcium,  
milk, vitamin B, vitamin D, selenium, and ever use of oral contraceptives have been shown to 
be protective for rectal cancer. High body mass index and little physical exercise are associated 
with colon cancer, but is negligible for rectal cancer (3). Persons with a first degree family 
relative with colorectal cancer have a two-fold risk of developing bowel cancer compared to the 
general population. Furthermore, persons with certain autosomal dominant conditions 
(hereditary non-polyposis colorectal cancer or familial adenomatous polyposis) constitute 5-
10% of all colorectal cancers (3). Screening with fecal occult blood testing has been 
demonstrated to reduce mortality rates by 15-33%, whereas screening with flexible 
colonoscopy, computerized tomography (CT), and molecular screening in feces or blood is 
under investigation (7). 
 
2.1.3 Staging 
The TNM (Tumor, Node, Metastasis) classification is used to describe the anatomic extent of 
cancer growth (Table 1), in which T1-T4 designate increasing local growth of the primary 
tumor and N and M indicate the presence (N1, N2, M1) or absence (N0, M0) of metastatic 
lymph nodes or distant metastasis, respectively.  
 
Table 1. Staging of rectal cancer used both clinically and pathologically (8, 9) 
T0 No evidence of primary tumor 
Tis Carcinoma in situ: intraepithelial or invasion into lamina propria 
T1 Tumor invades submucosa 
T2 Tumor invades muscularis propria 
T3 Tumor invades subserosa or non-peritonealized perirectal tissues 
T4 Tumor directly invades other organs or structures and/or perforates visceral 
peritoneum 
N0 No regional lymph node metastasis 
N1 Metastasis in 1 to 3 regional lymph nodes 
N2 Metastasis in 4 or more regional lymph nodes 
M0 No distant metastasis 
M1 Distant metastasis 
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Other useful staging systems are frequently used clinically (Dukes’ A-D, International Union 
Against Cancer – UICC stage 0-IV), but these classifications are today based on defined TNM 
stages. Almost all rectal tumors are adenocarcinomas originating from the glandular epithelium 
of the rectum and they are classified by histologic grade; low, intermediate and high 
differentiation, in which the less differentiated tumors tend to be more aggressive with less 
favorable prognosis (10). Rectal cancers may also be graded by the distance from the anal verge 
as high (upper 1/3 of rectum), medium (middle rectum), or low (lower 1/3 of rectum) which 
influences treatment (surgical techniques, radiation fields) as well as treatment outcome with 
lower cancers having higher risk of disease recurrence (11). An involved circumferential 
resection margin (CRM, see below) or CRM of less than 2 mm are highly associated with local 
recurrence and poor survival (12, 13), thus, CRM status is crucial for treatment and prognosis 
and are therefore reported during staging of the disease. 
 
2.1.4 Locally advanced rectal cancer – LARC 
An exact definition of LARC has not unambiguously been established (14), and the term has 
also changed during recent years due to increasing knowledge of risk factors of local failure and 
improvement of disease staging with the use of magnetic resonance imaging (MRI) (15, 16). 
The classic definition is a rectal tumor that by clinical or radiological assessment grows through 
the rectal wall, or has lymph node spread to an extent precluding complete removal by surgery 
alone. Resectable LARC is defined more strictly as tumors with penetration through the entire 
rectal wall, or with evidence of involved pelvic nodes, but still a non-threatened CRM based 
upon preoperative MRI and without distant metastasis (3), whereas non-resectable LARC 
usually comprises fixed tumors for which surgery is not possible without leaving tumor tissue 
within the pelvis. The latter tumors may after neoadjuvant treatment become resectable (17). 
The locally advanced tumors constitute at least 50% of all rectal carcinomas including the 
primary non-resectable tumors which constitute about 10-15% of all cases (18).  
 
In current clinical practice in Norway, preoperative CRT is given to patients with primary 
resectable and non-resectable tumors, i.e all T4 tumors, T3 tumors with MRI predicted CRM  
3 mm or any T stage with N+ tumors with MRI predicted CRM  3 mm (19, 20). These criteria 
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were used for inclusion in the LARC-RRP study (described below), also including patients with 
resectable metastases (usually a single liver or lung metastasis). In this thesis, rectal cancers in 
which preoperative CRT with a curative intention is indicated constitute the definition of 
LARC. 
  
2.1.5 Treatment of LARC 
 
Surgical treatment 
Surgery is the main treatment for rectal cancer with the aim of achieving radical resection 
margins. When feasible, low anterior resection (LAR) is performed. The tumor with margins is 
removed en bloc and a colorectal or coloanal anastomosis is made. A temporary diverting 
stoma may be performed in order to relieve the anastomosis during the postoperative period. 
When LAR is not feasible, especially in tumors located close to the anal verge, an 
abdominoperineal resection (APR) is performed. The rectum is removed and a permanent 
terminal colostomy is made. In some cases, Hartmann’s procedure is performed for tumor 
removal. The distal rectal stump is closed and left in the pelvis, and a permanent terminal 
colostomy is made (21). If the tumor has invaded neighboring organs (e.g. bladder, vagina, 
uterus, prostate, coccyx), curative surgery may require partial or total resection of these organs 
or even pelvic exenteration including cystectomi (22).  
 
Total mesorectal excision (TME) was introduced by Heald et al. in 1982 (23) and the technique 
was further improved in 1993 (24). TME has been shown to reduce local recurrence and 
improve survival (25), and is now considered the gold standard in rectal cancer surgery. The 
mesorectum refers to the fatty connective tissue layer 2-3 cm in thickness with associated 
vessels, lymphatics and lymph nodes, which surrounds the rectum and is enveloped by a fascia 
(the mesorectal fascia). TME refers to total surgical removal of this soft tissue envelope, but the 
resection can also be partial (PME) for tumors situated in the upper rectum. TME was 
implemented as the standard surgical technique in Norway in 1993 as part of a national project 
(26), and improved results on a national basis have been reported (27).  
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Figure 2. Sagittal section of the rectum illustrating a locally advanced rectal cancer with 
lymphatic metastatic spread in a male. The broken line shows the surgical dissection plane 
using the TME technique. Grey arrow indicates the shortest distance from tumor to the 
mesorectal fascia, i.e. CRM status. Adapted from British Journal of Surgery 1982 with 
permission (23). 
 
Neoadjuvant radiotherapy (RT) 
Since surgery is the principal treatment, any supplementing oncologic treatment is adjuvant 
(literally to help) to surgery. Often, adjuvant treatment is given after surgery, however, in the 
case of LARC, it may be applied before and is thus called neoadjuvant therapy. 
  
The rationale for combining radiotherapy (RT) and surgery is based on the observation that 
surgery has its limitation in the periphery of the tumor due to the need of preserving vital 
structures adjacent to the lesion. On the other hand, RT has its main effect in the margins of the 
tumor, and less effect in the central part of the tumor due to hypoxia-induced radioresistance 
and the huge amount of tumor cells needed to be killed. The surgical limitation in the periphery 
of the tumor is demonstrated by the association between histopathological involvement of 
resection margins (CRM positivity) and local recurrence rates, metastasis, and overall survival 
in patients only receiving surgery with TME technique (20, 28). Hence, tumor sterilization of 
the surgical periphery with adjuvant RT has been used for a long time, and two prospective 
randomized trials conducted in the 1980s demonstrated improved outcome with the use of 
postoperative RT in LARC (29, 30). At Memorial Hospital for Cancer and Allied Diseases in 
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New York, Stearns and colleagues established preoperative RT in the late 1950s (31, 32), which 
resulted later in a long-lasting discussion whether RT should be given pre- or postoperatively. 
A randomized controlled German trial found preoperative RT to be superior to postoperative 
RT with respect to local control and toxicity, but overall survival was not significantly different 
between the two groups (33). A systematic review concluded that adjuvant RT decreases the 
risk of local failure by 50-70% if given preoperatively, but 30-40% if given postoperatively in 
doses of more than 30 Gy, and there is strong evidence that preoperative RT improves survival 
by 10%. Furthermore, in patients presenting with a surgically non-resectable tumor, 
preoperative RT can cause tumor regression allowing subsequent radical surgery in a 
substantial proportion of patients (34). It has also been suggested that preoperative RT 
facilitates sphincter-preserving procedures by decreasing the size of the tumor (33, 35), 
however, this was not significant in a Cochrane systematic review (36). Thus, preoperative RT 
is now considered standard treatment in LARC at least in the European health community (37-
39).  
 
RT may be given as a short course (5 Gy in 5 consecutive days, also called “Swedish style RT” 
after a Swedish phase III trial (40)) or more protracted courses with 1.8-2 Gy per fraction 5 
days a week for 5-6 weeks to total doses of 45-50.4 Gy. The optimal schedule is still a matter of 
controversy, however, studies indicate that long course RT regimens are superior to the short 
course schedules with respect to downstaging, free resection margins, local recurrences, 
sphincter preservation, and probably late normal tissue toxicity (41). The protracted course is 
also easier to combine with chemotherapy. On the other hand, the short course schedule has less 
surgery delay, is generally less expensive, more convenient for the elderly and others with 
transportation difficulties, and is easier to complete for patients with poor compliance. 
 
Adjuvant chemoradiotherapy (CRT) 
Adenocarcinoma of the rectum is a radiosensitive tumor, and RT has the potential to eradicate 
the disease as a sole modality. Radical curative doses for adenocarcinoma at other sites would 
normally be considered to be greater than 70 Gy. However, this dose is too high because rectal 
and small-bowel toxicity would be unacceptable (42). If chemotherapy is given together with 
RT, it may potentiate the effect of RT. This radiosensitizing effect of the chemotherapeutic 
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agent will be discussed in detail later. Additionally, but not equally important in concomitant 
CRT in the treatment of LARC, it is claimed that undetected circulating tumor cells, or 
micrometastasis, outside the surgical specimen and the radiation field, may be eradicated by 
chemotherapy (43).  
 
5-fluorouracil (5-FU) has been used in colorectal cancer therapy and in combination with RT 
for decades (44, 45), and has been extensively studied in CRT regimens for the last two decades 
as adjuvant treatment in LARC. Three randomized controlled trials have all concluded that the 
addition of 5-FU to adjuvant RT in LARC improves local control and increases respectability, 
but without influencing survival or rate of sphincter preservation (18, 46, 47), with the 
exception of one trial showing increased disease-free survival in the most advanced non-
resectable cancers (18). Importantly, these studies also show increased but tolerable acute 
toxicity (14). A newly reported Cochrane systematic review concluded that, compared to 
preoperative RT alone, preoperative CRT enhances histopathological response and improves 
local control in resectable LARC but does not benefit disease-free or overall survival. The 
effects of preoperative CRT on functional outcome and quality of life are not completely 
understood and should be addressed in future trials (48). 
 
Capecitabine is an oral pro-drug that is converted to 5-FU in tissues, and it has potential 
advantages to intravenously (iv) administered 5-FU which will be discussed later. Capecitabine 
has been proven to be as effective as 5-FU in metastatic colon cancer with favorable toxicity in 
phase III trials (49). Emerging data from phase II trials of neoadjuvant regimens in LARC, in 
which capecitabine has been substituted for 5-FU, are encouraging (50), and a randomized 
phase III trial is still recruiting patients (NSABP R-04 study) (51). 
 
In summary, the standard treatment protocol used in Norway for LARC is preoperative RT, 50 
Gy in daily 2 Gy fractions (Monday through Friday) with concomitant 5-FU based 
chemotherapy, which is either 5-FU (400 mg/m2) 30 minutes before fractions 1, 2, 11, 12, 21 
and 22 combined with 100 mg Leucovorin® (“Nordic schedule”) or capecitabine (825 mg/m2) 
twice daily Sunday to Friday during RT. The RT is usually given with three-dimensional 
conformal treatment planning with 23 fractions of 2 Gy to the clinical target volume (tumor and 
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threatened lymph nodes) followed by a boost of 2 fractions of 2 Gy to the macroscopic tumor, 
resulting in a total dose of 50 Gy. Surgery is usually performed 6-8 weeks after the last 
radiation dose to allow for tumor shrinkage and the patient to recover (19). At our institution, 
each patient is evaluated by a multidisciplinary team composed of surgeons, oncologists and 
radiologists. In addition, histopathologists and specialist nurses should be included. 
 
 
2.1.6 The clinical trials LARC-RRP and PRAVO 
Currently, at the Norwegian Radium Hospital, two clinical trials are ongoing with relevance for 
the work conducted in this thesis. The LARC-RRP study (Locally Advanced Rectal Cancer – 
Radiation Response Prediction) is a phase II trial (ClinicalTrials NCT00278694) that started to 
enroll patients in October 2005. Eligible patients have primary LARC, and the treatment 
protocol includes two 2-weekly cycles of neoadjuvant chemotherapy (NACT) (oxaliplatin 85 
mg/m2 day 1, 5-FU 500 mg/m2 with folinic acid 60 mg/m2 day 1 and 2 – “Nordic FLOX”), and 
4 weeks after start of NACT RT is given as described for standard treatment with the use of 
capecitabine 825 mg/m2 twice daily on RT days and with the addition of oxaliplatin 50 mg/m2 
once weekly during RT (Figure 3). Tumor biopsies are sampled before start of treatment and 
are snap frozen immediately. Patients are examined before, during, and after CRT with 
magnetic resonance spectroscopy (MRS) as well as standard MRI. The surgical specimens are 
examined by an experienced pathologist, and the radiation response is classified by tumor 
regression grade (TRG) 1-5, in which TRG 1 represents pathological complete response (no 
tumor cells left) and TRG 5 corresponds to no radiation response with differential grades of 
histopathological tumor responses between these extremes (52). Patient follow-up takes place at 
the institution, and data will be compiled for 5 years postoperatively. The tumor biopsies are 
hematoxylin-eosin (HE) stained for validation of tumor content, and the biopsies will be 
analyzed further with ex vivo MRS and gene expression and kinase activity microarray with the 
aim of finding predictive molecular and metabolic tumor profiles of response.  
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therapy
NACT CRT Surgery Follow-up
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1          2          3         4          5         6 7         8         9   ...         15-17      Weeks
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•MRS
•Kinase activity profiling
•Gene expression profiling
Statistical analyses
 
Figure 3. Time line of treatment and selected examinations in the LARC-RRP study. Figure 
made by author. 
 
The Pelvic Radiation and Vorinostat (PRAVO) study is a phase I trial (ClinicalTrials 
NCT00455351) in which vorinostat, a histone deacetylase (HDAC) inhibitor, also called 
suberoylanilide hydroxamic acid (SAHA)1 and licensed in the US as Zolinza™, is combined 
with pelvic RT in advanced cancers with palliative intent. Patients with advanced pelvic 
cancers (mostly rectal and colon primaries, but also one gastric primary) have received 
palliative RT to macroscopic tumor with a fractionation dose of 3 Gy to a total dose of 30 Gy 
with concomitant oral vorinostat in sequential escalating doses. RT is given 3 hours after 
administration of vorinostat, and tumor biopsies are sampled at approximately the same time 
point and before treatment for correlative laboratory analyses (e.g. detection of histone 
acetylation). Toxicity and tumor response are monitored. The first patient was included in 
February 2007, and the accrual is about to finalize at the time this is written. The rationale for 
combining vorinostat with RT has resulted from the interest of our research group in combining 
HDAC inhibitors with RT (paper II and III). A PRAVO II study is currently being planned in 
preparation in which LARC patients will receive vorinostat in addition to standard 5-FU based 
CRT. In the view of new molecular targeting agents in neoadjuvant treatment of LARC, this 
                                                 
1 Vorinostat is the oral clinically used form of SAHA. In experimental settings SAHA was used, whereas 
vorinostat was given to patients in the PRAVO study. 
 19
study was the first to combine an HDAC inhibitor with RT with basis from pre-clinical 
evidence. 
 
2.1.7 Prognostic factors and response evaluation 
The terms prognostic and predictive factors may be somewhat overlapping, however, 
prognostic factors define the risk of recurrence or death of a standard treatment, whereas 
predictive factors indicate the likelihood of response to a given therapy and may therefore 
select patients for individualized therapy (53). Some prognostic factors may function as 
surrogate end point in clinical trials, as these factors are highly correlated to overall survival or 
disease-free survival. Surrogate end points are used since trial end points based on overall 
survival requires waiting for a minimum of 5 years to observe reliable results (54). 
 
TNM stage is historically the most important prognostic factor in most cancer types. 
Importantly, TNM staging may be clinically or radiologically assessed before or after (prefix y) 
neoadjuvant therapy or histopathologically staged by use of the surgical specimen following 
surgery (prefix p). Tumor depth, namely T stage, is important as T1 and T2 tumors have 
excellent long time survival, whereas T3 tumors, which make up 80% of rectal tumors seen in 
clinical practice (55) and T4 have more variable prognoses, thus, the newest edition of the 
TNM classification suggests an optional expansion of classifying extramural spread (9, 55, 56). 
Norwegian men diagnosed during 1998-2002 with rectal cancer had a 5 year survival of 86.2%, 
66.0% and 10.5% for localized (T1-2), regional (T3-4), and metastatic stage (M1), respectively 
(1). Lymph node metastases and the number of involved lymph nodes are independent 
prognostic factors for survival with prognosis deteriorating when more than 4 lymph nodes are 
involved as assessed histopathologically (20, 54).  
 
CRM is the shortest distance from tumor to the non-peritonealised bare area of the rectum 
located both anteriorly and posteriorly, i.e. the anatomical plane the surgeon dissects through 
during TME surgery. After the introduction of the concept of CRM more than 20 years ago (12, 
57), CRM has been shown to be an even more significant prognostic factor than TN stage, as 
involvement strongly predicts local recurrence, development of distant metastases, and overall 
survival (58, 59). A minimum distance of 1 mm appeared to discriminate between high (85%) 
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and low risk (3%) with respect to local recurrence, however, the number of millimeters are still 
under debate, and in general, it can be stated that the larger the CRM, the better the prognosis 
(59). CRM is correlated to TN-stage, tumor size, differentiation grade, vascular invasion, 
degree of stenosis and ulcerative tumor growth patterns, distance to anal verge, surgical 
technique and age, and most of these factors are also correlated to prognosis (59). Preoperative 
high resolution MRI can predict CRM with high accuracy (60, 61) and can therefore be used to 
select patients for neoadjuvant treatment. Macroscopic (R2) or microscopic (R1) presence or 
absence (R0 resections) of residual disease, i.e. tumor in the margin of the surgical specimen, is 
also highly correlated to local recurrence and survival (62). 
 
The degree of response after CRT is also important for prognosis. Pathological complete 
response (pCR) has been associated with increased overall survival in prospective studies (63, 
64), however, even though the addition of 5-FU to neoadjuvant treatment in LARC increased 
the rate of pCR, overall survival was not improved, thus it has been claimed that modest 
increase in pCR does not impact on survival (54). The interval between CRT and surgery, 
tumor size, and how assiduous the pathologists search for viable tumor cells influence the rate 
of pCR, and if there are tumor cells left in the specimen, there exists no method to assess the 
true viability of these cells. Since the majority of patients treated with preoperative CRT do not 
achieve pCR, TRG scoring systems have been developed based on the amount of residual 
tumor cells and the extent of fibrosis in the bowel. The first scoring system was developed for 
oesophageal cancer following CRT using a five-point scale (65), and different variations of this 
system has been employed for rectal cancer (52, 66-68). In the LARC-RRP study, TRG scoring 
system after Bouzourene was used (Table 2), and TRG have been shown to be independent 
prognostic indicator for long-term local tumor control and disease-free survival (52, 63). Since 
different TRG systems are used, comparison between trials has been difficult. Hence, a 
suggestion of a standardized four-point scale TRG has been proposed recently (69). 
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Table 2. Tumor Regression Grade – TRG, from Bouzourene et al. (52) 
TRG1 Absence of residual tumor and fibrosis extending through the different layers 
of the rectal wall, i.e. pCR 
TRG2 Presence of residual tumor cells, ranging from one single tumor cell to tumor 
cells scattered throughout the fibrosis 
TRG3 Increase in the number of residual cells compared to TRG2, but fibrosis still 
dominates 
TRG4 Residual tumor outgrowing the fibrosis 
TRG5 Absence of any tumor regression (no fibrosis) 
 
2.1.8 Molecular response prediction 
The varying response to neoadjuvant CRT indicates tumor heterogeneity among LARC 
patients. It is not known why such large differences in response occur, but the phenomenon 
may reflect diverse intrinsic biology of tumors or yet undetected external factors. CRT delays 
surgery by several months, is expensive, has acute and long-term side effects, and may increase 
perioperative morbidity (36, 48, 70), thus, the possibility to predict response either before or in 
the early stages of treatment may spare poorly responding patients from undergoing treatment 
that is not beneficial. Patients with no response after CRT might probably go straight to surgery 
omitting CRT or be candidates for alternative or more intensive CRT regimens (71), and 
patients with a complete remission would benefit from omitting surgery (72). At present, no 
reliable technique (radiological or clinical) for predicting tumor response after CRT is available 
(42, 73), and it has been concluded that pre-treatment T stage, N stage, histological grade, 
differentiation, age and gender do not reliably predict histological response to CRT (70). 
Extensive research based on histological and molecular assessment of pre-treatment tumor 
biopsy specimens or blood samples have been employed in order to elucidate factors that may 
allow for response prediction.  
 
Pretreatment serum level of carcinoembryonic antigen (CEA) of >2.5 ng/ml has been associated 
with lower pCR rates, and in conjunction with high tumor circumferential extent (>60%) and 
tumor distance of >5 cm from the anal verge, response to CRT has been predicted using these 
factors (74). The tumor suppressor protein p53 is the most extensively studied single molecular 
predictor of response to CRT in LARC. Only 4 out of 18 studies utilizing 
immunohistochemistry (IHC) found that p53 expression significantly predicted response (70), 
however, IHC can not always discriminate between wild-type and mutant TP53 gene. 
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Assessment of TP53 mutations by gene sequencing analysis has revealed association between 
p53 gene mutations and response rates (75, 76). High endogenous expression of the cell cycle 
inhibitor protein p21by IHC correlated to good response following CRT (77), however, 
contrary to this finding, pretherapeutic p21-positive biopsies were shown to be associated with 
poorer disease-free and overall survival compared to p21-negative tumors (78), hence, its role 
as predictor in this setting remains controversial.  
 
EGFR is expressed in 50-70% of colorectal carcinomas and upregulation of the protein is 
associated with aggressive tumor growth, poor prognosis, and resistance to radiation in pre-
clinical and clinical studies (79, 80). Accordingly, low EGFR expression in pretreatment 
biopsies is associated with favorable response and prognosis (81, 82). Even so, contradictory 
results also exist for this marker. A high gene copy number of EGFR was associated with tumor 
regression following a cetuximab-containing CRT regimen (83) and, secondly, the combined 
analysis with low EGFR and high VEGF was recently shown to predict radioresistant tumors 
with high accuracy (84). VEGF alone (in plasma or IHC-based) has not shown correlation to 
tumor response, but high expression was an indicator of poor disease-free survival linked to 
distant metastasis (85, 86). In a single study, growth hormone receptor overexpression was 
significantly associated with poor tumor response (87).  
 
DNA damage repair factors may be of importance in predicting radiosensitivity. Microsatellite 
instability, which is a defect in the DNA mismatch repair pathway, is found in 95% of 
hereditary and 15% of sporadic colorectal cancers, and is of importance for prognosis (88). 
Three studies did not show any predictive value of microsatellite instability for treatment 
response in LARC (70), but high expression of the DNA double-strand break (dsb) repair 
proteins Ku70 and Ku86 was associated with decreased response to CRT in a single study (89). 
Low telomerase activity has in pre-clinical experiments been related to radiosensitivity, and 
pre-treatment tumors with high telomerase reverse transcriptase protein stain have been shown 
to be radioresistant, which was also correlated to recurrence and survival (90). 
 
The ability to evade apoptosis is thought to be central in both tumorigenesis and resistance to 
cytotoxic drugs and radiation. The level of spontaneous apoptosis in pretreatment rectal cancer 
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biopsies has been evaluated in seven studies. In six of those, a high apoptotic index was 
associated with good response after CRT (70). Furthermore, survivin, an inhibitor of apoptosis, 
was inversely correlated to the apoptotic level, and was also correlated to disease-free survival 
and metastasis development (91). The pro-survival protein Bcl-2 and pro-apoptotic Bax were of 
no predictive value (70). 
 
As radiation and cytotoxic drugs mainly kill proliferating cells, the proliferative index has been 
evaluated in pretreatment biopsies. Mitotic activity, as assessed by mitotic cell fraction, 
proliferating cell nuclear antigen, or the proliferative marker Ki-67, has shown different results, 
and a review concluded that proliferating index unlikely predicts response to CRT in LARC 
(70, 92-94). A high flow-cytometric S-phase fraction in aneuploid tumors was shown to be 
associated with local recurrence, but tumor response was not evaluated and no correlation was 
found in diploid tumors (95). Thymidylate synthase and thymidine phosphorylase are thought 
to be important for 5-FU based therapy, and gene expression was found to be lower in 
responders compared to non-responders following 5-FU based CRT (96). 
 
A wide range of other factors have been tested with no or only weak correlation to tumor 
response following CRT. The most important are COX-2, caspase-8, APC, DCC, cleaved CK-
18, APAF-1, MLH-1, MSH2, and MIB-1 (78, 84, 93, 97, 98). 
 
One of the most intriguing molecular developments has been the use of pretreatment gene 
expression profiling. At present, four studies have evaluated gene expression of pretherapeutic 
rectal cancer biopsies as a predictive tool of CRT response (71, 99-101). Ghadimi et al. found 
in a cohort consisting of 30 patients that a set of 54 genes could predict T-level downstaging 
with 78% sensitivity and 86% specificity, but there was no correlation to TRG. A second study 
by Watanabe et al. used TRG as response criterion, and found discriminating expression of 33 
genes in 35 patient samples. A prediction model was made of 17 patients (testing set) and an 
accuracy of 82% of predicting poor versus good responders was found. In a third study, Kim et 
al. were able to discriminate pCR (TRG 1) from partial responders (TRG 2-4) in a total of 46 
patients, using a similar approach as Watanabe, and finding a prediction accuracy of 87% in the 
15 validation test samples. In a study by Rimkus et al., 43 patients were predicted to be either 
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good responders (< 10% tumor cells in the surgical specimen) or partial/poor responders (> 
10% tumor cells in the resected material) with 71% sensitivity and 86% specificity by the use 
of 42 discriminating genes. Notably, the response criteria were different in the three studies. 
Nevertheless, in the future, gene expression profiling may assist in response prediction, 
although validation in larger, independent studies is required. 
 
A clinically useful predictive test would be simple to perform, easy and fast to evaluate, would 
give reproducible results, and would have a high sensitivity and specificity. Potential predictors 
need to be validated in prospective clinical trials followed by interventional studies, i.e. studies 
that include a therapeutic decision based on the results of the predictive test (53). In conclusion, 
none of the above-mentioned molecular markers has been found useful, mainly because no 
marker has shown high enough sensitivity and specificity for being capable of detecting 
responders or non-responders. Furthermore, the markers have not yet been rigorously tested on 
a large scale. At present, existing molecular data is not sufficiently reliable but the possibility of 
combining clinical, radiological, and molecular information to tailor treatment for LARC 
patients is intriguing. A novel methodological platform for molecular prediction is suggested in 
paper IV. 
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2.2 Radiation 
 
The discoveries of X-rays in 1895 by Wilhelm Conrad Röntgen and of natural radioactivity by 
Henry Becquerel a few months later were a breakthrough that paved the way for a new era in 
science and cancer treatment. As early as in 1896, Emil Grubbé treated an advanced ulcerated 
breast cancer with X-rays in Chicago. In 1898, Marie Curie discovered a natural source of -
rays, namely radium, which was the only source of -rays for cancer treatment for 20 years 
(102). In the beginning, single large doses were used, however, in the 1920s, side-effects of 
radiation became apparent. Claude Regaud sterilized ram testes with radiation and discovered 
that a single dose caused necrosis of the skin, however, if radiation was delivered in small daily 
fractions over a period of weeks, the animal could be sterilized with a minimal scrotal skin 
reaction. In this way, fractionated RT was born. Furthermore, in 1912, it was discovered that 
skin reactions were less severe if the radiation source was pressed tightly to the skin (102). 
Later the direct correlation between radiosensitivity and access of oxygen was discovered (103, 
104). In 1955, Thomlinson and Gray proposed that oxygen levels within a tumor decreased 
with the distance from the capillary within a tumor and that radioresistant hypoxic cells might 
re-grow if allowed to re-oxygenate after radiation therapy (105). These initial and other later 
scientific efforts formed the basis of the safe and effective RT being used today, which is the 
second most effective treatment modality in cancer after surgery (106, 107). Even though RT 
still has a role as monotherapy for some cancer presentations, it is more commonly used as a 
component of multimodality managements, and more than half of all cancer patients require RT 
during at least one stage of their care (106). 
 
Ionizing radiation consists of subatomic particles (e.g. alpha and beta particles, neutrons) or 
electromagnetic waves (photons) in the short wavelength end of the electromagnetic spectrum 
(X-rays and -rays) and is energetic enough to detach electrons from atoms or molecules 
(ionizing them). RT is the medical use of ionizing radiation as part of cancer treatment and may 
be used in a curative or palliative setting. The source of ionizing radiation for use in external 
beam RT is most commonly a linear electron accelerator (linac) (Figure 4). Until quite recently, 
radioactive material like cobalt-60 was used, which is still important in developing countries 
and for research purposes. The absorbed dose of ionizing radiation in tissues is measured in Gy 
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(Gray), and 1 Gy is the absorption of 1 Joule per kilogram of water. The old term rad is still in 
use, and 100 rad is equal to 1 Gy.  
 
The ability to delineate normal and adjacent tumor tissue by CT/MRI/PET scans has improved 
during recent years. Furthermore, the development of two- and three-dimensional treatment 
planning, intensity-modulated RT and image-guided RT has provided the basis for better 
ensuring accurate beam placement to allow higher doses to be applied within the target volume 
while simultaneously protecting adjacent normal organs (102).  
 
 
Figure 4. The author is preparing for irradiation of mice at the Radiation Department, 
Norwegian Radium Hospital, using a linac. 
 
2.2.1 Radiobiology 
As high-energy radiation traverses a cell, it mainly interacts with electrons, ejecting some of 
them from atoms (ionization) and raising others to higher energy levels within an atom or 
molecule (excitation). These resulting secondary electrons may excite or ionize other nearby 
atoms, giving rise to a cascade of ionizing events. Ionization and excitation lead to breakage of 
chemical bonds and formation of broken molecules (107). A 1-Gy X-ray dose results in 105 
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ionization events per cell, producing 1-2000 single-stranded breaks (ssb) and 40 dsb of the 
DNA. Cells undergo a critical period after irradiation, which determines their fate: death, 
repaired damage, or continued growth and division without complete repair (106). Most 
decisive of cell fate is the induction of both ssb and dsb in DNA but damages to the cell 
membrane and other structures may as well be important. These cellular events initiate very 
complex signaling cascades on the molecular level that result in a variety of responses, 
including cell cycle arrest, DNA repair and apoptosis (programmed cell death) (Figure 5) (108). 
Another phenomenon is the bystander effect, whereby irradiated cells exert effects on 
neighboring unirradiated cells, thought to be mediated by diffusible substances (109, 110). 
Hence, not only the tumor cells but also the tumor microenvironment (e.g. the host stromal 
component within a tumor) contribute to radiation responsiveness (106). 
 
Figure 5. A simplified overview of some of the cellular pathways involved in response to 
ionizing radiation. Reprintet with permission from Cancer Research 2009 (106). 
 
Cellular radiosensitivity is influenced by intrinsic factors, such as phase of the cell cycle, 
activation of apoptotic programmes, DNA break repair proficiency and accumulation of genetic 
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mutations in oncogenes and tumor-suppressor genes, and extrinsic factors such as oxygen, 
nutrients and metabolic waste elimination (102). To selectively kill tumor cells and spare 
normal tissue, the response of tumor tissue must be greater than that of normal tissue for the 
same radiation dose, i.e. a favorable therapeutic index (Figure 6). 
 
 
 
 
Figure 6. Therapeutic index (arrow) as function of radiation dose. A favorable outcome implies 
that the response of tumor tissue is greater than that of normal tissue (large therapeutic index), 
in contrast, similar responses of tumor tissue and normal tissue implicate an unfavorable 
outcome (small therapeutic index). Figure made by author. 
 
As Claude Regaud discovered at an early stage, a series of fractionated radiation doses, instead 
of using one single large dose, amplify the therapeutic differential between normal tissue and 
the tumor for several reasons. These are easily recollected as the 4 Rs, as described by Withers: 
Repair, repopulation, redistribution and reoxygenation (111). DNA repair capacity differs 
between tissues, and in general, normal tissues like connective tissue, kidney, and spinal cord 
are capable of greater repair than malignant tissues if allowed enough time after a radiation 
dose. Thus, by spacing dose fractions by at least 6 hours (normally 24 hours), the DNA damage 
recovery in normal tissue is greater than that of tumor. Because cell killing is logarithmic rather 
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than linear, the difference in each day’s effect is amplified exponentially. During an extended 
course of RT, cells that survive irradiation proliferate (repopulate) and thereby increase the 
number of cells that must be killed when the next dose is given. The rate of repopulation in the 
average tumor is less than that of normal tissues. This regenerative response allows normal 
tissue (e.g. mucosa) to tolerate a larger dose over time. Redistribution, or reassortment, is based 
on the differential sensitivity to radiation in different phases of the cell cycle. Cells that survive 
a first dose of radiation tend to be in a resistant phase of the cell cycle and within a few hours, 
they may progress into a more sensitive phase. Late-responding normal tissue tends to be 
essentially static in the division cycle, in a phase that allows repair. Cell cycle with relation to 
radiation will be discussed later.  
 
The response of cells to ionizing radiation is strongly dependent on oxygen (103). Without 
oxygen, the free radicals induced by ionizing radiation will react with free protons, thereby 
“neutralize” the effect of the free radicals (107), i.e. hypoxia causes relative radioresistance. 
Tumors larger than 1 mm in diameter become partially hypoxic due to poor vascularization 
(112), whereas normal tissues are normoxic. After a single dose of radiation, the surviving 
tumor cells are mainly from the hypoxic cell fraction. Subsequent to radiation, the hypoxic 
fraction falls, i.e. the tumor is reoxygenized, by means of different mechanisms, resulting in 
increased radiosensitivity (107).  
 
These 4Rs modify the response of a tissue to repeated doses of radiation and are responsible for 
the increased therapeutic index. A fifth R was proposed by Steel et al, namely intrinsic 
radiosensitivity (113). Different tumors and different tissues respond in a varying degree to the 
same single dose of radiation, i.e. are harboring different radiosensitivity, which should be 
considered together with the above mentioned 4 Rs as a determinant of response.  
 
In conventional RT, daily fractions of 1.8-2.0 Gy to a weekly dose of 9.0-10 Gy are normally 
used. More than one fraction per day (hyperfractionation) with at least 6 hours in between to 
allow sufficient repair in normal tissues may also be used (102). 
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Cell cycle and radiation 
A cell proliferates by performing an orderly sequence of events, in which it duplicates its DNA 
content and divides in two identical daughter cells. This cycle of events is known as the cell 
cycle. The cell cycle is divided into four defined phases: S, M, G1 and G2 phase. During the S 
(synthesis) phase, DNA synthesis occurs and in M (mitosis) phase, chromosome segregation 
and cell division take place. Between S- and M-phases are the two regulatory “gap” phases, G1 
and G2 which are important for cell cycle regulation (114).  
 
Cell cycle checkpoints are mechanisms by which the cell actively halts progression through the 
cell cycle until it can ensure than an earlier process, such as DNA replication or mitosis, is 
complete (115). The G1 phase contains an important restriction point before the cell enters S 
phase. If conditions are unfavorable, the cell can delay progress through G1 or even enter a 
specialized resting state known as G0. The cell can remain permanently in G0 or until growth 
signals tell it to recommence cell division (114). Ionizing radiation causes breaks in the 
phosphodiester bonds in the backbone of the DNA helix. When two of these breaks are close to 
each other, but on opposite DNA strands, a dsb is present and the cell faces a particularly 
challenging situation for repair. To accomplish this, an arrest of cell cycle progression is rapidly 
engaged through the activation of ATM (ataxia telangiectasia mutated), which is a kinase that 
phosphorylates numerous substrates upon activation. Among them, the transducer kinases 
CHK1 and CHK2 increase the level of p53, this in turn increases transcription of the gene for 
p21, an inhibitor of cyclin dependent kinases (CDK). The Cyclin E/CDK2 complex promotes 
G1-S phase transition through phosphorylation of the retinoblastoma protein (which in turn 
releases transcription factors necessary for entry into S phase), and inhibition of these events by 
p21 leads to G1 phase arrest and allows the cell to repair the DNA damage before DNA 
replication is to occur in S phase. The G2 checkpoint prevents cells to enter mitosis when the 
cell experiences DNA damage when in G2 phase or when G1 checkpoint fails (such as in cells 
defective in p53). ATM, through CHK1, inhibits a family of phosphatases called cdc25, that 
normally activate CDK1 at the G2/M boundary (Figure7) (115). 
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Figure 7. Simplified overview of the cell cycle and checkpoint activation after DNA damage. 
Given functional checkpoints, ionizing radiation induces both G1 and G2 phase arrest. Figure 
made by author. 
 
There are several aspects of how the cell cycle and its regulation are important with respect to 
ionizing radiation. Mutations in genes encoding factors of the regulatory pathways, as described 
above, are major contributors to the development of cancer (116). After radiation, normal cells 
are allowed to stop cycling to ensure DNA repair, whereas cancer cells harboring defect 
checkpoint activation will continue to cycle, passing through mitosis with unrepaired DNA 
breaks and lethal chromosomal aberrations, and progressing into mitotic cell death (also known 
as mitotic catastrophe), which is considered the most important death mechanism caused by 
ionizing radiation (108). Furthermore, the radiosensitivity of cells varies considerably as they 
pass through the cell cycle. Cells in G2, M, and G1 phases are relatively radiosensitive 
compared to cells in S phase, and this principle is used in both fractionated RT and 
experimentally with radiosensitizers to synchronize cells in a relatively radiosensitive phase of 
the cell cycle before radiation is applied (107). 
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DNA damage and repair following radiation 
Ionizing radiation induces several types of damage to DNA, including ssb, dsb, DNA-protein 
cross-link, base damage, intra-strand cross-link and inter-strand cross-link. Most of these 
aberrations are successfully repaired by different mechanisms. However, the incidence of cell 
killing is only strongly correlated to the amount of DNA dsb (107) and, secondly, if dsb is left 
unrepaired or repaired improperly, dsb causes chromosomal aberrations such as translocations, 
amplifications, or deletions, which may be lethal or result in oncogenic transformation (117). A 
cell’s ability to survive following radiation is highly dependent on intact dsb repair systems 
(118), which is also exemplified by patients harboring mutations in genes involved in these 
repair systems, e.g. patients with ATM or NBS1 mutations, who are prone to cancer 
development and have severe normal tissue reactions following RT (107). Based on these 
observations, it is generally believed that dsb lesions are critical for cell killing by radiation. 
 
At the site of a dsb, a multiprotein complex is rapidly formed. This can be visualised by 
immunostaining and is known as ionizing radiation-induced foci. It is not known in detail how 
dsb is recognized but ATM has a particular affinity for DNA ends, and this end-binding activity 
suggests that ATM might be a sensor for DNA dsb (117). Histone H2AX is rapidly 
phosphorylated by ATM (resulting in H2AX) along the dsb site, and this protein assists in the 
assembly of other repair proteins (among them the NBS1 protein) (119). There are two major 
pathways for repairing dsb; homologous recombination (HR) is a highly accurate process that 
requires large regions of homologous sequence as a template, whereas non-homologous DNA 
endjoining (NHEJ) simply joins broken ends together, thereby often generating deletions, 
insertions, or base pair substitutions. As HR requires a homologous sequence of DNA (a sister 
chromatid) to repair the dsb, this repair pathway is taking place only in late S-phase, M-phase 
and in the G2-phase. NHEJ is the main pathway in the G0-, G1- and early S-phase (Figure 8) 
(117). 
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Figure 8. Non-homologous endjoining (NHEJ) and homologous recombination (HR) are the 
two main pathways involved in DNA dsb repair following ionizing radiation. Figure made by 
author. 
 
Tumor cells often harbor defects in DNA dsb repair genes and these mutations give rise to 
genomic instability and facilitate cancer development (115). Following radiation exposure, 
tumor cells are more prone to lethal unrepaired DNA damage than that of normal cells. Cell 
cycle regulation and DNA dsb repair are tightly coordinated through p53, and if cells are not 
repaired efficiently, p53 may induce apoptotic cell death. Important for cell death following 
radiation is the slow death response of mitotic catastrophe, where cells may die within 1-2 turns 
of the cell cycle related to misrejoining during mitosis caused by persistent dsb (108, 120). In 
addition, certain irradiated cells will remain metabolically active but incapable of division, a 
situation called senescence or sustained cell cycle arrest (108).  
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Radiosensitivity 
Radiosensitivity is described by the radiation dose required to produce a defined level of cell 
inactivation (107). In 1956, Puck and Marcus developed an assay to quantify cell killing – the 
cell survival assay, also called clonogenic survival assay (121). This technique is based on the 
fact that one reproductively viable cultured cell can divide infinitely and generate a large 
colony of cells, and cells that fail to form self-sustaining colonies may undergo limited numbers 
of cell divisions forming undetectable microcolonies, remain as single cells or disappear. The 
most extensively used model to describe radiation effects in cells is the linear-quadratic 
formula, defining cell survival as S = (e-[d + d
2])N, in which S = surviving fraction, d = dose per 
fraction,  represents the linear initial slope of the line (at 0 dose).  is a measure of the 
downward curvature of the line at higher doses (the quadratic component of cell killing), and N 
is the number of fractions. Using a single fraction, the formula therefore is S = e-[d + d
2] (122). 
A cell survival curve is a plot of the surviving fraction as function of radiation dose. The 
survival curves are normally plotted on a logarithmic scale (Figure 9).  
 
The linear quadratic model assumes that lethal radiation damage is created in either of two 
ways: as a consequence of a single ionizing event (e.g. a dsb) or of two separate sublethal 
ionizing events that interact pairwise to create lethal damage (e.g. two closely ssb). In the latter 
case, the damage is considered repairable if allowed enough time between the two sublethal 
events. Thus, the amount of lethal damage from the last component is dependent on repair rate 
of sublethal damage. α and β can be interpreted as the probability of inducing the first and the 
second form of damage, respectively, and the α/β value represents the dose at which the two 
types of damage are equal. At doses less than α/β, the first type of damage predominates, and at 
doses above, the second type of damage predominates. Tissues possessing small α/β are said to 
have more sparing capacity than those with higher α/β values. This means that a reduction in 
dose per fraction will reduce cell kill relatively greater in low α/β-value tissues in tissues with 
high α/β-values  (123). The explanation is mainly that tissues with a low α/β also have a long 
repair half-time, which is the time required between fractions for half of the maximum possible 
repair to take place (107). 
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Figure 9. Clonogenic survival of the colon carcinoma cell line RKO (squares), mean of three 
independent experiments and bars representing ± one standard deviation. The black curved line 
shows the linear quadratic relationship between cell survival (surviving fraction) and radiation 
dose, plottet on a log-linear scale, and fits well into survival of RKO cells following a single 
fraction of radiation. The curved grey line and the linear grey line indicate the two components 
of cell killing. At the intersection between these two lines, the two components of cell killing is 
equal, and this occurs at a dose of 2.5 Gy, i.e. α/β = 2.5 Gy (indicated by the vertical linear 
line). Data partly from paper III, figure made by author. 
 
 
In normal tissues with rapidly proliferating cells (acute responding tissues, e.g. intestinal 
epithelium, bone marrow and skin), the α/β is relatively high (as for tumors), and severity of 
acute side effects increases with increasing dose and is seen during or within a few weeks after 
treatment. These effects are transient compared to responses seen in late-responding tissues 
(such as subcutaneous tissue, brain, kidney, liver, intestinal wall), in which adverse effects are 
seen months or years after RT and are often progressive. The severity of acute effects increases 
with increasing dose (as cell kill of tumor tissue), while late side-effects are more sensitive to 
changes in fraction size (124). For late responding normal tissues, the expected biological 
equivalent dose (BED) is described as BED = D × [1 + d/(α/β)], where D is the total radiation 
dose and d is the dose per fraction. Using this formula, one can calculate the change in total 
dose necessary to achieve equal tissue response when the dose per fraction is varied. By 
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optimizing fractionation schedules, it is possible to spare late responding tissues with a 
relatively smaller effect on tumor cell kill, thereby increasing the therapeutic index (107, 123). 
 
2.3 Chemoradiotherapy (CRT) 
 
2.3.1 Rationale for combining RT with chemotherapy 
In a clinical setting, the aim of combining chemotherapy with RT is to improve local control. 
The introduction of a second modality (chemotherapy) potentially increases both tumor cell kill 
and normal tissue toxicities, and in order to evaluate benefits, the concept of therapeutic index 
is essential. Therapeutic gain is only achieved if the combined-modality regimen results in 
improved tumor response under comparable levels of toxicity. Otherwise, the improved effect 
could have been obtained by merely increasing the radiation dose (107). 
 
In 1979, Steel and Peckham proposed several potential advantages of combined chemotherapy 
and RT (125). Spatial cooperation describes the situation in which disease in some particular 
anatomical site that is missed by one therapeutic agent is dealt with adequately by another. By 
this modality, RT aims to control local disease, whereas chemotherapy aims to control disease 
outside the radiation field, e.g. distant micrometastasis. Toxicity independence refers to when 
two partially effective anticancer agents can be given without any requirement for reducing the 
individual doses and because of independent differential and acceptable toxicity profiles, 
additive improvement in therapeutic result can be expected (effect of agent A + B). For neither 
of the mentioned mechanisms, interaction between the modalities is needed. Protection of 
normal tissues refers to a possible agent that allows a greater dose of radiation to be given than 
would have been tolerated otherwise. This will be therapeutically beneficial only if tumor cells 
are not similarly protected. At last, enhancement of tumor response is the situation in which 
administration of one agent apparently increases the effect of another or in which the effect of a 
combination appears to be greater than would be expected. For both of the two latter 
mechanisms, interaction between concomitantly administered modalities will take place. 
Enhanced tumor response may also be caused by an indirect interaction by killing 
subpopulations resistant to the other modality and may, therefore, not necessarily change the 
survival curve as seen below. 
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In cell survival curves derived from clonogenic experiments, interaction between modalities 
would mean a change in the shape of the curve. If the steepness of the dose-response curve is 
increased (bending down), the response is enhanced (radiosensitization) and in the case of 
protection, the curve is bending up. If chemotherapy results in a fixed amount of cell kill, but 
no interaction occurs, the dose-response curve will shift to a lower surviving fraction without 
changing its shape. To more easily compare the shape of curves, the curve of the combined 
chemotherapeutic agent together with radiation is usually normalised to the cytotoxic effect of 
the chemotherapeutic agent alone (Figure 10) (107). An important limitation using the 
clonogenic assay is that it relies on established tumor cell lines (since normal cells are difficult 
to grow in cultures and if they do, they are not considered normal any more) and can not be 
used to assess effects in normal tissues. Secondly, the above mentioned non-interactive 
mechanisms of advantages in combined chemotherapy-radiotherapy treatment can only be 
assessed in animal or clinical trials (102).  
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Figure 10. Cell survival curve of RKO cells exposed to radiation only (squares) or pretreated 
with 100 nM Trichostatin A (TSA) for 18 hours before radiation exposure (circles). Mean of 3 
independent experiments, and bars representing one standard deviation. The cytotoxic effect of 
TSA alone was 49 ± 5% (mean ± one standard deviation) (gray line). The TSA-treated radiation 
curve is normalized to this effect, which makes it easier to see a downward bending of the 
curve, i.e. that exposure of TSA before radiation is applied sensitizes the cells to the effect of 
radiation. Data from paper III, figure made by author. 
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A new framework for considering drug-radiation combinations has been suggested after Steel 
and Peckham, encompassing five mechanisms (126). Spatial cooperation is mentioned above, 
and important for this mechanism is full-dose of both modalities. The modalities are typically 
administered sequentially, as in the case with NACT given before CRT in the LARC-RRP 
study. Only clinical trials or metastatic animal models can demonstrate this effect. Cytotoxic 
enhancement is the strategy described above in which the in vitro clonogenic survival curve is 
modulated and tumor cells are sensitized to radiation. For this mechanism, the drug must be 
present at time of or in proximity to radiation. Biological cooperation refers to strategies that 
target distinct cell populations, such as a drug that target the radioresistant hypoxic fraction of 
the cells in a tumor. Temporal modulation is an approach to enhance the tumor response to 
fractionated therapy, and typically, the two modalities should be delivered concomitantly or in a 
rapidly alternating schedule. Candidate drugs could for instance be inhibitors of DNA repair 
selective for tumor cells. Normal tissue protection was also proposed by Steel and has been 
discussed above. An example is stimulation of stem-cell proliferation in early-responding 
tissues. 
 
Interaction between chemotherapy and RT may be explained by several mechanisms, and for 
most agents several interactions apply at the same time (43): 
• DNA damage may be caused by both chemotherapy and RT, and a non-lethal ssb may 
become more difficult to repair if, for instance, a cisplatin adduct is close to the ssb.  
• Chemotherapy can inhibit post-radiation damage repair. DNA synthesis and repair share 
common pathways, which provide the rationale for using DNA synthesis inhibitors, 
such as 5-FU, together with radiation.  
• Administered concurrently, RT and chemotherapy often target different phases of the 
cell cycle, such as 5-FU targeting the S phase cells and radiation targeting the other cell 
cycle phases.  
• Some drugs are also able to synchronize the cells within the cell cycle, to allow 
increased efficacy of subsequent RT (also called cell cycle pooling).  
• Targeting of hypoxic cell fraction in a tumor with a drug has been discussed, but also 
shrinking of the tumor mass will increase perfusion and oxygenation of the cells in a 
tumor and reduce the radioresistant cell fraction.  
 39
• Repopulation of rapidly proliferating tumors is usually mediated by overactivation of 
growth factors or downstream signalling pathways, and agents that target S phase of the 
cell cycle (5-FU) as well as growth factor pathways (EGFR inhibitors) may effectively 
prevent tumor cell repopulation thereby sensitize tumor cells to radiation.  
• Inhibition of prosurvival and “poor prognosis” markers, e.g. EGFR inhibition. 
 
2.3.2 5-fluorouracil/capecitabine 
5-FU is a halogenated pyrimidine nucleoside analogue and its metabolites impede nucleic acid 
synthesis through thymidylate synthase inhibition, thereby depleting the pool of nucleotide 
triphosphates and causing inhibition of DNA synthesis. Furthermore, the metabolites are also 
incorporated into RNA and DNA, thus inhibiting both transcription and protein synthesis (127). 
The drug has been used in treatment for colorectal cancer for decades (128), and is also 
extensively used with radiation. It is often combined with folinic acid since this drug enhances 
and prolongs the inhibition of thymidylate synthase caused by 5-FU. When 5-FU is given 
concomitantly with RT, a lower and non-cytotoxic concentration is typically used, and 
radiosensitization has been demonstrated in experimental models (129, 130). Interaction 
between ionizing radiation and 5-FU is caused by several mechanisms (131). 5-FU kills 
radioresistant S phase cells, and the drug causes increase in tumor blood flow and abrogation of 
radiation-induced G2-arrest. Depletion of thymidine also inhibits repair of DNA dsb. 
Sensitization is enhanced in cells defective in the G1 checkpoint (e.g. mutated TP53) since these 
cells progress into S phase after radiation and are then killed by 5-FU. Preclinical studies 
suggest that 5-FU should be present for a prolonged period before, during, and after radiation 
for optimal radiosensitization (129). However, 5-FU, which is administered intravenously, and 
its active metabolites have short half lives (132), which led to the search of oral prodrug 
alternatives.  
 
Capecitabine is a fluoropyrimidine carbamate that is converted to 5-FU in a 3-step enzymatic 
reaction in vivo, the final step involving thymidine phosphorylase. Thymidine phosphorylase 
has higher concentrations in many tumor types compared to normal tissue and, secondly, 
radiation itself can selectively induce thymidine phosphorylase activity in tumor tissue (133). 
Toxicity of 5-FU primarily involves rapidly proliferating tissues and includes epithelial 
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ulceration throughout the gastrointestinal tract (mucositis, esophagitis, gastritis, colitis with 
diarrhea, nausea/vomiting) and myelosuppression (128). Capecitabine has correspondingly 
gastrointestinal side effects, but less myelosuppression, and may cause painful swelling and 
erythema in the hands and under the feet, as well as fatigue (134). 
 
2.3.3 Oxaliplatin 
Cisplatin has been used for anticancer therapy since the 1970s and has improved the prognosis 
in ovarian and especially testicular cancer. However, cisplatin has little effect in colorectal 
cancer and is associated with severe side effects (renal toxicity, nausea, neurotoxicity). In an 
attempt to overcome these side effects, less toxic platinum analogues were developed, and as a 
result, carboplatin and, later, oxaliplatin were discovered (135). As previously discussed, 
oxaliplatin was found to be effective in combination with 5-FU in metastatic colorectal cancer, 
and disease-free survival was improved when oxaliplatin was added to 5-FU based adjuvant 
treatment in stage II and III colon cancer (136). Importantly, oxaliplatin increases both 
gastrointestinal and myelosuppressive side effects caused by 5-FU and sensory neuropathy is 
common in patients receiving this drug (135).  
 
Oxaliplatin shows similar chemical behaviour and has comparable mechanisms of action as 
other platinum derivatives. Its antitumor effects are thought to be related to Pt-DNA adducts, 
but irreversible binding to proteins may also contribute. DNA adducts are formed in guanine 
and adenine, and since Pt may attach to two different nucleotide bases, both intra- and 
interstrand links are created. This in turn will modify the three-dimensional DNA structure, 
which inhibits normal DNA synthesis and repair. Binding of oxaliplatin to proteins will 
normally inactivate their function and enzymes important in repair of the DNA adducts may 
covalently bind to oxaliplatin and impair their function (137). If substantial DNA damage 
persists, it may ultimately lead to activation of the apoptotic pathway and cell death (138). 
Furthermore, the effect of oxaliplatin and 5-FU in combination has in in vitro and in vivo 
experimental models shown synergistic effects, also in 5-FU resistant cell lines (137). 
 
Cisplatin acts as radiosensitizer (139) and is a commonly used drug in CRT for malignant 
diseases other than rectal cancer. The increased combined effects are caused by radiation-
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induced enhancement of cellular uptake of the drug, inhibition of DNA repair, cell cycle 
perturbations, and production of more lethal DNA damage (43). This and the above mentioned 
increased effect of oxaliplatin seen in clinical trials in colon cancer led to the hypothesis that 
oxaliplatin as a novel chemotherapeutic agent in LARC could improve preoperative CRT 
results, both in terms of local control and prevention of distant metastases (140). Oxaliplatin 
has been incorporated in treatment of LARC in many studies, both as NACT, adjuvant 
chemotherapy and concomitantly with 5-FU based CRT. In the latter, the main aim is to 
increase local control by sensitizing cells to radiation (141). However, at least in the beginning 
of the work of this thesis, preclinical evidence of oxaliplatin as radiosensitizer was scarce, 
which led to questioning whether oxaliplatin might act as radiosensitizer in preclinical models 
(paper I).  
 
2.3.4 Histone deacetylase inhibitors 
Cancer has traditionally been considered to be a disorder of genetic defects, such as gene 
mutations and deletions or chromosomal abnormalities that result in loss of function of tumor-
suppressor genes or gain of function or hyperactivation of oncogenes. However, gene 
expression may be altered by epigenetic changes, which have been shown to be crucial to the 
onset and progression of cancer (142). Epigenetics is the study of heritable changes in gene 
expression that are not due to any alteration in the DNA sequence (143). Examples are 
chromatin remodelling causing changes in the access of transcription factors to genes and DNA 
methylation, in which methyl group are bound to cytosine residues, thereby silencing the gene 
without changing the genetic code.  
 
The packaging and compaction of DNA into chromatin is critical for essentially all DNA 
metabolic processes, including transcription, replication and repair. The primary repeating unit 
of chromatin is the nucleosome, which consists of 147 base pairs of DNA wrapped around an 
octameric structure composed of two copies of the four core histones; H2A, H2B, H3 and H4. 
These are dynamic structures that can be altered by at least three different processes; 
incorporation of histone variants (e.g. -H2AX important for DNA repair), replacement, 
repositioning, or removal of nucleosomes by chromatin remodelling complexes that alter access 
to DNA, and finally, chromatin structure can be modified by coordinated post-translational 
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modifications on histone residues such as acetylation of lysines, serine phosphorylation, 
methylation of lysines and arginines, or polyribosylation and ubiquitylation (144). Most of 
these modifications are reversible, and since the changes are not necessarily heritable, it has 
been questioned whether these modifications are truly epigenetic (145). 
 
Ac AcAc
HATHDACHDACinhibitor
Open chromatin structure, available for transcription
Chromatin compaction, transcriptionally inactive
 
Figure 11. Function of HDAC inhibitors. DNA (red) is wrapped around a histone octamer 
(blue). Lysine residues (green) on histones are targets for acetylation. The opposing effects of 
histone acetyl transferases (HATs) and histone deacetylases (HDACs) regulate gene expression 
through transferral or removal of acetyl groups (yellow) to histones, respectively, leading to 
changed accessibility of regulatory proteins to DNA. HDAC inhibition will lead to 
hyperacetylated histones. Figure made by author. 
 
The most studied of these modifications is histone acetylation, which is regulated by histone 
acetyl transferases (HATs) and histone deacetylases (HDACs) as shown in Figure 11. 
Generally, histone acetylation promotes a more relaxed chromatin structure, allowing 
transcriptional gene activation (145, 146). However, specific patterns of histone acetylation and 
deacetylation are influenced by other histone modifications, such as methylation. Together, 
these post-translational modifications generate a “histone code” and additionally, cross-talk 
between histone modifications and DNA methylation also occurs, demonstrating the 
complexity of transcriptional regulation by histone acetylation (147). Importantly, HDACs also 
have many non-histone protein substrates that regulate cell proliferation and death and 
therefore, the alternative name “lysine deacetylases” instead of HDAC has been suggested. 
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Acetylation can either increase or decrease function or stability of these proteins. 18 HDAC 
enzymes have been identified. Class I HDACs (HDAC1, 2, 3 and 8) are localized in the nucleus 
and ubiquitously expressed, whereas class II HDACs (HDAC4, 5, 6, 7, 9 and 10) are localized 
both in the nucleus and cytoplasm and are tissue-restricted in expression. These two classes 
have a zinc ion at the catalytic pocket and are inhibited by hydroxamates, as will be discussed 
below. Class III HDACs, also called sirtuins, are not inhibited by these compounds. Class IV 
HDAC consists of HDAC11 (146).  
 
HDACs are required for cell cycle progression and are aberrantly recruited to promoter regions 
of tumor-suppressor genes in many cancers, thereby repressing those. In addition to recruitment 
of HDACs to specific loci, different HDACs are overexpressed in many tumor types, such as 
HDAC2 and HDAC3 in colon cancers. Correspondingly, global hypoacetylation of histone H4 
is a common hallmark of tumors (142). During the last decade, targeting HDACs with 
inhibitors has become an emerging therapeutic concept. In the 1970s, sodium butyrate was 
observed to cause morphological reversion of a transformed cell phenotype and later, the 
compound was found to be an HDAC inhibitor. Today, numerous HDAC inhibitors are 
available and may be classified according to their chemical structures or which HDACs they 
inhibit: Hydroxamates (e.g. TSA and SAHA which inhibit class I and II), benzamides (e.g. MS-
275 which inhibits class I), cyclic peptide (e.g. depsipeptide inhibits class I) and the aliphatic 
acids (e.g. valproate and butyrate which inhibit class I and II). The quest for inhibitors of 
specific HDACs is ongoing, and the only one found is tubacin, which inhibits HDAC6 only, 
and is responsible for acetylation of tubulin with no effect on histones. Whether or not these 
specific inhibitors will have lower toxicity profiles while maintaining anticancer activity 
remains to be determined (142). 
 
Expression levels of 7-10% of all genes were altered using a twofold change as a cut-off value 
in various cell lines following incubation with HDAC inhibitors from all 4 classes mentioned 
above, and the compounds were found to induce about as many genes as were repressed (146). 
The therapeutic potential of HDAC inhibitors stems from their capacity to selectively induce 
cell death in tumor cells at concentrations that are minimally toxic to the host. Apoptosis is 
induced by both the extrinsic and intrinsic apoptotic pathway due to alteration of the pro- and 
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antiapoptotic balance or due to activation of specific proteins upstream of these pathways. Most 
known HDAC inhibitors induce G1 arrest, which is mediated through p53 independent 
activation of p21 and inhibition of DNA synthesis proteins, whereas G2 arrest is a much rarer 
event. The compounds also have anti-angiogenic effects caused by downregulation of pro-
angiogenic genes (142). 
 
HDAC inhibitors are used in clinical trials as single agent therapy, in combination with 
chemotherapeutic agents, and recently, in combination with RT (148). The potentially favorable 
combinatory use with RT is based on preclinical data. All tested HDAC inhibitors have shown 
radiosensitization in vitro and for four of the drugs, this has also been demonstrated in vivo (for 
MS-275, Valproic acid, depsipepside and CBHA). Paper II includes the fifth of these, namely 
SAHA. Based on in vitro experiments, a correlation between histone hyperacetylation and 
enhancement of radiosensitivity was suggested, and hyperacetylation should be present both 
before and sustained some time after radiation exposure to induce optimal sensitization. 
Furthermore, histone acetylation was proposed as a molecular marker in the design of treatment 
protocols when combining HDAC inhibitors and RT to comply with the in vitro findings (149). 
The role of histone acetylation as a molecular marker is further exploited in paper II.  
 
No radiosensitization by HDAC inhibitors has been observed in fibroblasts, normal breast, and 
intestinal cells, suggesting a selective effect on tumor cells. The mechanisms of enhanced 
radiation response are only partially understood. Inhibition of DNA dsb repair as measured by 
prolonged H2AX foci following radiation is detected, whereas repair of other types of DNA 
damage has not been identified. This may be due to decreased levels of DNA dsb repair 
proteins (Ku70, Rad51) but could also be due to acetylation of DNA repair proteins (ATM, 
Ku70, p53). The number of DNA dsb is increased following combinatory exposure, suggesting 
that change in chromatin structure makes cells more vulnerable to form dsb. Cell cycle arrest as 
described above may also contribute, but low nontoxic concentrations of HDAC inhibitors that 
do not induce cell cycle effects have a radiosensitizing effect as well (149-151).  
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SAHA 
SAHA and TSA are similar in chemical structures, and both bind to the zinc ion in the catalytic 
pocket of class I and II HDACs and act as non-specific pan-HDAC inhibitors. TSA is a 
naturally occurring antifungal compound and was the first high-affinity inhibitor to be 
identified. TSA is quite cytotoxic and is unstable under in vivo conditions, thus this compound 
is not recommended for treatment of patients, although the compound has proven to be 
important in studying HDAC inhibition effects in vitro (149, 152). In contrast, SAHA alters 
cellular acetylation patterns and causes growth arrest and death in a wide range of transformed 
cells, both in vitro and in animal tumor models, and at concentrations that are non-toxic to 
normal cells (148). In vitro experiments suggest tumor cell lines to be 10-fold more sensitive to 
SAHA-induced cell death than normal fibroblasts (153). Among the numerous novel HDAC 
inhibitors being tested in clinical trials, SAHA is the only compound approved by the US Food 
and Drug Administration (October 2006; for treatment of cutaneous T-cell lymphoma). The 
most common adverse effects by SAHA are fatigue, diarrhea, thrombocytopenia and 
dehydration (152). 
 
SAHA regulates expression of 2-10% of all genes. Mostly studied is the induction of p21, 
which induces G1 phase arrest. SAHA causes changes in the promoter region of p21, whereas 
no change has been found in genes not regulated by SAHA, hence, suggesting selectivity in 
altering gene expression (154). SAHA also down-regulates expression of thymidylate synthase, 
consequently, exposure to SAHA prior to 5-FU induced synergistic effects between these two 
compounds in colorectal carcinoma cells (155). Increased acetylation levels of transcription 
factors (p53, HIF-1, E2F) and cytoplasmic proteins (-tubulin, cortacin, heat shock protein 90) 
may also contribute in SAHA-induced cell cycle arrest, cell death, and the inhibition of tumor 
growth seen in many xenograft models, although the specific mechanism of action is not 
known. Interestingly, SAHA given to carcinogen-treated rats and mice reduces tumor 
incidence, multiplicity, and volume. SAHA has shown synergistic activity in combination with 
a wide range of chemotherapeutic agents (e.g. kinase inhibitors, cytotoxic agents) (148). In 
vitro, SAHA radiosensitizes cell lines from various cancers and has been shown to increase the 
number of radiation-induced DNA dsb and repair of dsb as assessed by H2AX foci (156). This 
is probably mediated by inhibition of the NHEJ pathway, apparently by reducing the expression 
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of repair related genes such as Ku70, Ku80, Rad50, DNA-PK, and Rad 51. Acetylation of p53 
helps stabilizing the protein following DNA damage and may contribute to radiosensitization 
by pooling cells in the G1 cell cycle phase. Cell cycle arrest has already been mentioned as a 
possible mechanism (151). Presently, five clinical trials of the combined treatment with RT and 
SAHA are registered in addition to the PRAVO study (157). 
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3 Aims of the study 
 
Preoperative chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC) is intended to 
shrink intrapelvic tumor to facilitate complete surgical removal, with the intention to improve 
local tumor control. However, the effect of CRT may vary from complete response to lack of 
objective response; also, preoperative CRT postpones surgery and has adverse effects. Thus, the 
two most important challenges in preoperative CRT in LARC are to improve treatment efficacy 
and to predict response to enable treatment stratification. 
 
The main objectives of this work were: 
I To assess potential radiosensitizing effects of oxaliplatin and SAHA in relevant 
colorectal carcinoma cell line and xenograft models (paper I and II) 
II To investigate the relevance of HDAC2 deficiency for radiosensitization by HDAC 
inhibition in colorectal carcinoma cell lines (paper III) 
III To determine whether kinase activity profiles in pretreatment tumor biopsies can predict 
tumor response to preoperative CRT in LARC (paper IV) 
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4 Summary of papers 
 
Paper I: Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal 
carcinoma: Does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity? 
 
The aim of this investigation was to study potential radiosensitizing properties of oxaliplatin in 
colorectal carcinoma cell lines in the absence and presence of 5-FU, and to examine whether 
the addition of oxaliplatin to capecitabine and radiation might improve radiation-induced tumor 
growth inhibition in a colorectal carcinoma xenograft model.  
 
In vitro, a 2-hour pre-exposure of oxaliplatin to two different cell lines enhanced the effect of 
radiation in a concentration-dependent manner. Combining oxaliplatin with post-radiation 
exposure to 5-FU enhanced the radiosensitization seen with 5-FU alone. Oxaliplatin exposure 
caused delayed G2/M phase arrest, however, since this occurred after radiation was applied, a 
possible cell cycle pooling in these radiosensitive cell cycle phases could not explain the 
radiosensitization observed in vitro.  
 
In the in vivo model, mice bearing bilateral xenografts were treated with daily 2-Gy radiation 
fractions Monday through Friday for two consecutive weeks and were given oral capecitabine 
on the same days as RT was applied. Oxaliplatin was administered once weekly (Mondays). 
Capecitabine alone did not inhibit tumor growth, but when combined with oxaliplatin, growth 
inhibition was significant and comparable to the inhibition seen with radiation alone. 
Capecitabine enhanced radiation-induced tumor tumor growth delay but the addition of 
oxaliplatin to this regimen did not significantly improve the effect.  
 
Taken together, this work demonstrates in vitro radiosensitizing effect of oxaliplatin with or 
without 5-FU, however, this effect was not seen in the in vivo situation, questioning the 
rationale for incorporating oxaliplatin into 5-FU based CRT regimens in LARC. 
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Paper II: Radiosensitization by SAHA in experimental colorectal carcinoma models – in vivo 
effects and relevance of histone acetylation status 
 
In this work, SAHA was evaluated for its ability to induce histone acetylation and to enhance 
radiation effects in in vitro and in vivo colorectal carcinoma models. Furthermore, the general 
assumption that histone hyperacetylation at time of radiation exposure is required to obtain 
optimal combinatory effects, was questioned.  
 
In vitro, SAHA caused rapid induction of H3 and H4 acetylation, which was lost within 3 hours 
after removal of the compound. Radiosensitization, as assessed by clonogenicity, was observed 
when the radiation was applied at time of H3 and H4 hyperacetylation following SAHA 
exposure. Furthermore, radiosensitization was also seen, but to a lesser degree, when radiation 
was applied 3 hours after SAHA removal, on restoration of baseline histone acetylation. 
 
In vivo, increased xenograft histone acetylation was detected 0.5-3 hours after intraperitoneal 
(ip) injection of SAHA in two xenograft models. No accumulation was seen following daily 
SAHA injections for 5 days. Fractionated RT combined with daily SAHA treatment caused 
significantly increased tumor growth delay compared to radiation alone, whereas SAHA 
monotherapy had no or only a modest effect on tumor growth. Radiation exposure 12 hours 
after SAHA injection, when histone acetylation levels were restored to baseline levels, also 
caused radiosensitization in vivo and surprisingly, in one of the xenograft models, a 
significantly improved effect compared with the situation when radiation was applied at 
maximal histone acetylation was observed. Acetylation of p53 and tubulin was detected with 
similar kinetics as for histones.  
 
In conclusion, pre-exposure to SAHA induced both in vitro and in vivo radiosensitization. 
Hyperacetylation at the time of radiation exposure did not seem to be a permissive requirement 
for radiosensitization, suggesting that the usefulness of measuring histone acetylation as a 
biomarker in determining optimal treatment schedules of HDAC inhibitors in combination with 
RT is debatable.   
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Paper III: HDAC2 deficiency and histone acetylation 
 
This paper was a correspondence to the Nature Genetic letter by Ropero et al. in 2006 (158). 
The authors had hypothesized that an HDAC2 inactivating mutation in colon cancer cells may 
predict response to HDAC inhibitors. The background was their finding that histones H3 and 
H4 were not hyperacetylated following a 24-hour incubation with 250 nM TSA in HDAC2-
mutated cell lines (RKO and Co115) compared to wild-type HDAC2 cell lines. Furthermore, 
the HDAC2-mutated cell lines were resistant to TSA with respect to apoptosis, cell cycle arrest 
and xenograft growth. The authors concluded that cell lines with mutated HDAC2 may show 
impaired responsiveness to TSA, which may have potential relevance for the pharmacogenetic 
selection of cancer patients to be treated with HDAC inhibitors. 
 
Our research group was intrigued by these results and wanted to use this model to study the 
relevance of histone acetylation for radiation effect of HDAC inhibitors. The intention was to 
expose HDAC2-mutated colorectal carcinoma cell lines to HDAC inhibitors to observe whether 
radiosensitization was induced or not in cells that had lost the propensity of histone 
hyperacetylation upon TSA exposure. However, when reexamining the results from Ropero et 
al, we found that TSA (100 and 250 nM) induced transiently increased hyperacetylation of H3 
and H4, which was restored to baseline levels after ~12-18 hours of continuous TSA exposure. 
This was shown in both RKO cells at our laboratory, newly purchased RKO cells from 
American Type Culture Collection (ATCC) and RKO cells kindly provided from Ropero’s 
research group. Among the three RKO variants, only RKO cells from Ropero’s research group 
were deficient in HDAC2 expression. To verify the identity of the RKO cell lines and to 
exclude inadvertent contamination or mislabeling, DNA fingerprinting analysis of the three 
RKO variants was performed. This examination revealed that the three cell lines most likely 
were from the same origin but that the cell line from Ropero harbored distinct discrepancies 
when compared to the other two variants.  
 
TSA treatment caused histone hyperacetylation as well as radiosensitization of RKO cells 
regardless of HDAC2 status and consequently, we believe that HDAC2 status need not be taken 
into account when investigating HDAC inhibitors as radiosensitizers in colorectal carcinoma.
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Paper IV: Prediction of response to preoperative chemotherapy in rectal cancer by multiplex 
kinase activity profiling 
 
Histological tumor response of rectal cancer to preoperative CRT varies from complete 
remission to no objective response. Activity of kinase signaling pathways has been shown to be 
predictor of radioresponse. This study aimed to investigate whether intrinsic kinase activity 
profiles of pretreatment tumor samples by use of a novel peptide array platform might predict 
the individual tumor responses to preoperative CRT in LARC. 
 
67 LARC patients were treated with two neoadjuvant cycles of oxaliplatin and 5-fluorouracil 
and subsequent CRT consisting of oxaliplatin, capecitabine, and radiotherapy before surgery 
was performed 6-8 weeks after CRT completion. Prospectively collected pre-treatment tumor 
biopsies were analyzed using microarrays with kinase substrates and the resulting substrate 
phosphorylation patterns were correlated with the individual tumor responses to the 
preoperative treatment as assessed by histomorphologic tumor regression grade (TRG). 
 
73% and 15% were scored as good responders (TRG 1–2) or intermediate responders (TRG 3), 
respectively, whereas 12% were assessed as poor responders (TRG 4–5). The ability to predict 
response to therapy was evaluated using leave-one-out cross-validation from phosphorylation 
patterns of 144 peptide substrates in the array using PLS-DA as classifier. In a subset of 7 poor 
responders and 12 good responders, treatment outcome was correctly predicted for 95%. When 
building a prediction model from these samples, correct prediction of 85% in the remaining 
patient samples was found. In tumors from poor responders, peptide substrate phosphorylation 
indicated significantly higher kinase activity mediated by signaling pathways implicated in 
radioresistance. 
 
Multiplex kinase activity profiling may assist in predicting tumor response to preoperative CRT 
in LARC. However, because the number of patients, especially poor responders, was limited, 
the ultimate robustness and clinical applicability of the analytical approach and the resulting 
classifier need to be evaluated in larger, independent studies.
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5 Methodological considerations 
 
Cell cultures 
In vitro cell cultures were used to study clonogenicity and biological effects of treatment with 
radiation and chemotherapy. All cell lines were originally derived from colorectal 
adenocarcinomas (Table 3).  
 
Table 3. Characterization of colorectal cell lines 
Cell line Derived 
from 
Anatomical site Patient 
(sex/age) 
Differentiation TP53 
status 
Established 
(year) 
Reference 
HT29 Primary Rectosigmoid Female/44 Moderate Mutated 1964 (159)1 
HCT116 Primary Colon Male/- Poor Wild-type ~1981 (160) 1 
RKO Primary Colon - Poor Wild-type ~1983 (161) 1 
SW620 Lymph node Colon Male/51 - Mutated 1971-5 (162) 1 
Co115 Primary Ascending colon Female/77 Poor Mutated 1976 (163) 
1Information was also found at www.atcc.org.  
 
Working with cell lines has obvious advantages: They grow continuously, have an unlimited 
lifespan, allow the performance of various experiments and based on their clonal origin, 
apparently have homogenous and specific phenotype and genotype. In addition, they are easily 
available and culture conditions are simple and easily standardized among different 
laboratories. However, cell lines in general are prone to genotypic, karyotypic and phenotypic 
drift during prolonged culture. In addition, sub-populations may arise by the selection of 
specific, more rapidly growing sub-clones that may result in inter- and intralaboratory cell line 
heterogeneity (164). Such changes make cell lines more and more different from their origin. 
Moreover, the origin of a cell line is often an aggressive and fast-growing tumor, which may 
not represent normal more slow-growing cancers in patients. Cell cultures also lack the normal 
microenvironment and importantly, cell-cell interactions between tumor and stromal cells are 
absent. Finally, a human tumor consists of many heterogeneous cancer cells with various 
phenotypes and genotypes. These features must be considered when translating pre-clinical cell 
line-based treatment effects into a clinical setting.  
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Cell line clonogenicity 
The classic assay from 1956 essentially tests every cell for its ability to undergo unlimited 
proliferation and reflects all modes of cell death, also when cells divide for a few cycles before 
dying. Compared to other faster and less laborious assays, it is considered the best assay to 
study radiation effects in vitro (165). Moreover, this assay has been shown to predict the 
response of drugs seen in animal xenograft models and to some degree clinical response (166, 
167). Still, it has to be kept in mind that effects in vitro do not necessarily translate into an 
effect of the same direction or magnitude in vivo. Typical problems are that drug concentrations 
in vitro are often higher than those that can be achieved in vivo and that the drugs are not 
homogeneously available to tumor cells in vivo. Furthermore, cell-cell interactions and 
microenvironmental factors known to be important for radiation sensitivity and resistance are 
more or less lacking (168).  
 
Experiments are performed in essentially two different modes: Cells may be plated before 
treatment, or cells are treated in dishes and subsequently plated in appropriate dilutions to 
assess clonogenic ability (169). For the experiments performed in this thesis, I used the first 
variant to avoid counting the cells more than once, which reduces the variation of the number of 
seeded cells between treatment modalities within the same experiment. However, the limitation 
is that the cells can not be treated too long because radiation must be applied after cells have 
attached to the bottom of the plates and before the cells start to divide. Radiation was always 
applied 24 hours after seeding, which allowed enough time to pre-treat cells but not allow cells 
to divide. 
 
Xenografts 
Subcutaneous growth of human tumor cell lines in immunodeficient athymic nude mice is a 
well established and accepted model, in which the tumor cells, in contrast to the situation in in 
vitro experiments, can interplay with the microenvironment (e.g. connective tissue, 
vasculature), hence, the model is considered more “natural” than monolayer growth of tumor 
cells in tissue flasks with unlimited access to nutrients. However, it may be discussed how 
“natural” colorectal cancer cells are when growing in subcutaneous tissue in a mouse. 
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Orthotopic models exist in which colorectal cancer cells grow in their organ of origin (170), but 
measuring radiation effects in such models is technically difficult.  
 
Figure 12. An athymic female nude mouse bearing bilateral HCT116 xenografts in the rear 
flanks. Picture made by author. 
 
Since establishment in 1975, xenograft models have contributed substantially in screening of 
treatment effects (171). Because mice with defective immune system do not reject the foreign 
tissue, the tumors usually grow unchecked unless stopped by effective treatment. However, 
xenografts do not behave like naturally occurring tumors in humans, e.g. they do not 
metastasize to other tissues. Xenografts, at least those used in the experiments of this thesis, 
have been established from cell lines being cultured for various time periods in vitro. Two 
concerns have been raised using xenograft models in treatment screening. Firstly, the treatment 
tested may appear effective in mice but work poorly in humans, and secondly, treatment with 
little effect in mice will not be further investigated and consequently, effective treatment may 
be missed. However, these models are the best available and ethically acceptable models we 
have. There is correlation between effects seen in xenograft models and human cancer, but 
without absolutely prediction of effects seen in the clinic (172). Thus, as for in vitro 
experiments, caution should be made when interpreting findings from xenograft experiments 
and only clinical trials can give the true answer. 
 
Flow cytometry analysis 
Cell cycle profiles were analyzed by means of flow cytometry. Cells were stained the 
propidium iodide fluorochrome, which binds to DNA. When excited by laser at 488 nm light, 
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propidium iodide can be detected using a 562-588 nm filter. DNA content in each cell can then 
be measured in thousands of cells per second by flow cytometry. Cells in G1 phase have two 
copies of each chromosome, whereas cells in G2/M phase have four copies (Figure 13). Cells in 
S phase have between two and four copies of their DNA. 
 
Figure 13. Cell cycle profile of HT29 cells as detected by flow cytometry. Number of cells as 
function of DNA content is shown. DNA content of 2n corresponds to two copies of each 
chromosome (G1 and G0 phase cells), whereas the double amount of DNA corresponds to cells 
in the G2/M phase as DNA replication has occurred during S phase. Data from paper I, figure 
made by author. 
 
Western blot immunostaining 
To detect protein expression, total protein lysates from cell cultures or xenografts were 
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to 
nitrocellulose membranes. The membranes were incubated with primary antibodies before 
incubation with a horseradish peroxidase-linked secondary antibody. Immunoreactive proteins 
were visualized by enhanced chemiluminescence. 
 
Radiation 
Whereas high-energy radiation from 60Co (Cobalt) sources was delivered to cells, both 60Co and 
a linear accelerator were used in the animal experiments. The dose rate used in paper I was 
lower than that of used in paper II because our institution received a new Cobalt source in the 
meantime. The linear accelerator was used because no Cobalt source was available for a 9-
month period. For in vitro experiments, up to 4 plates could be irradiated simultaneously by 
placing the plates in room temperature in the radiation field 80 cm from the source. Clinically 
relevant doses of 2 and 5 Gy were used. In the animal experiments, mice were placed so the 
 56
tumor was at least 10 mm inside the radiation field while the rest of the mouse was outside. 
Accurate radiation dose deposition was ensured by using both mini-ionization chambers and 
thermoluminescence dosimetry, and daily 2-Gy fractions were given Monday through Friday, 
similar to the fractionated RT given in a clinical setting.  
 
Figure 14. Anesthetized mice were aligned along the radiation field so that the tumors were 
kept inside the radiation field while the rest of the body was placed outside to minimize 
radiation deposition to other parts of the mouse (left). A 20 mm polystyrene build-up bolus was 
placed on top of the tumors to give homogeneous and maximal dose deposition within the 
target volume (right). Eye ointment was applied because mice do not close eyes during 
anesthesia. Picture made by author. 
 
In paper I, radiation was only applied to one side (unilaterally), whereas the contralateral tumor 
was the unirradiated control. This led to two problems. First, abscopal effects might have 
influenced growth of the unirradiated tumor. Second, the unirradiated tumor grew much faster 
than the irradiated and the mouse had to be killed before a 5-fold increase of the irradiated 
tumor was reached. Thus, in paper II, both sides of the mouse were irradiated by simply turning 
the mouse around, whereas control mice were not irradiated at all. 
 
Tumor growth delay 
In 1969, Barendsen and colleagues developed the tumor growth delay assay by using rats (173). 
By measuring tumor volume changes as function of time, radiation effects with and without a 
potential enhancer of the radiation effect can be quantified by looking at the time needed for a 
tumor to reach a specific volume, e.g. a doubling of the pretreatment volume. The difference in 
time needed to reach this volume in presence of a drug is defined as tumor growth delay.  
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This assay reflects the effect of treatment on clonogenic as well as non-clonogenic cells with 
proliferative activity. A limitation is that it does not measure those few clonogenic cells that 
survive after high-dose irradiation. Whether these few cells are killed or not determines the 
outcome of RT in a curative setting (174). An alternative animal tumor model has been 
suggested to be used in order to detect killing of these few resistant cells, namely the TCD50 
assay developed by Suit in 1966. In this assay, groups of animals bearing tumors of the same 
size are irradiated with different doses with and without the agent of interest and the mice are 
observed in a sufficient time period thereafter with respect to recurrence. By plotting the 
proportion of tumors that are locally controlled as a function of radiation dose, the dose at 
which 50% of the tumors are locally controlled (TCD50) can be determined. Theoretically, a 
single surviving proliferative cell left in the xenograft will then subsequently cause recurrence 
(102, 168). However, this assay needs a large number of mice, which raises animal ethical 
challenges. The assay is labor-demanding, expensive and difficult to perform using fractionated 
radiation. Additionally, curation by CRT alone is not yet the aim in LARC. This justifies 
measurement of tumor growth delay as the assay of choice when studying potential radiation 
response enhancement in LARC. 
 
Chemotherapy 
For in vitro studies, the chemotherapeutic agents were diluted in culture medium from frozen 
stock solutions immediately before addition to cell cultures. In the animal experiments, 
capecitabine was suspended in Arabic gum and then given to the mice orally by the use of a 
gavage. Oxaliplatin was given iv diluted in 5% glucose and SAHA was given ip diluted in 
dimethyl sulfoxide (DMSO). All agents were freshly made before use. For the animal 
experiments, the potential radiosensitizers were given daily or weekly, according to the 
protocols, in order to imitate the clinical situation as closely as possible. Capecitabine was 
given immediately before radiation and during anesthesia to minimize discomfort for the mice.  
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Kinase activity profiling 
 
Sample preparation 
In rectal carcinomas the tumor is normally available for biopsy sampling without causing too 
much discomfort for the patient and 3-5 biopsies were collected from each patient. Tumor 
content was assessed histologically in frozen sections, allowing microscopy guided rough 
dissection to remove normal tissue, increasing the relative proportion of tumor cells in the 
samples. Tumors are heterogeneous, usually with increased hypoxia and necrosis in the central 
part of a tumor compared to the peripheral part. The latter are usually more available for biopsy 
sampling, thus, the biopsies do not necessarily represent the inner gross mass of the tumor. 
Moreover, the effects on the biological samples of immediate freezing in liquid nitrogen, 
storage, handling, cutting and, finally, making lysates in room temperature are mainly 
unknown. These factors must be kept in mind when interpreting the results. 
  
Tyrosine Kinase PamChip® Array technology 
With the intention of studying kinase activity as potential predictor of CRT response, we chose 
the Tyrosine Kinase PamChip® Array technology (Figure 16), which allows functional 
comparison of biological samples that indicate the state of information flow mediated by 
kinases. Other methods, such as immunoblotting, IHC, mass spectroscopy, or enzyme-linked 
immunosorbent assay, identify phosphorylated proteins that represent the end products of 
kinase activity. An advantage of the technological platform is that small sample quantities are 
required, typically 2-5 μg total protein being sufficient. One main challenge of the used 
technology was that the computational tools for data analysis were at an early stage of 
development, and no general consensus approach to data validation existed. 
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Figure 16. Tyrosine Kinase Pamchip® Array technology. The 96-well Pamchip unit (lower left) 
is analyzed in the PamStation® (upper left). The PamStation® consists of a pump, which pumps 
the sample back and forth in each array (well) of the unit, and a specialized camera detects light 
intensity for each of the 144 peptides (upper right) induced by FITC-conjugated 
phosphotyrosine antibody bound to phosphorylated peptide substrates attached to the porous 
structure (lower right). A high degree of phosphorylation for a specific substrate leads to high 
signal intensity. Figure made by author. 
 
 
Data analysis 
The strategy for analyzing phosphopeptide signatures of the tumor samples and correlation to 
TRG was developed during the analytical process. The methods were derived from previously 
reported gene expression analysis and other high-throughput technologies in similar settings, 
but had to be adapted and the analysis is thoroughly described in the manuscript. It will be 
briefly summarized below with some specific comments.  
 
From each sample, the peptide substrate signal intensity was calculated by averaging technical 
replicates after removal of signal outliers. Correction for plate variation was necessary, and this 
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was performed by normalizing each peptide signal to the mean peptide signal intensity of the 
TRG 1-2 samples in each Pamchip®96 unit. After normalization, this variation was minimal 
(Figure 17).  
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Figure 17. Color map illustrating signal intensities before (left panel) or after (right panel) 
normalization to mean signal intensities of good responders (TRG 1-2) within each 
Pamchip®96 unit. Patient samples sorted according to three of the analyzed arrays (A, B and C) 
are shown along the horizontal axis and peptides along the vertical axis. Red means high signal 
intensity and blue represents low signal intensity. Clustering according to the arrays was seen in 
the non-normalized panel; in particular, array A samples are different from samples on arrays B 
and C. After normalization, no obvious clustering was seen. Figure made by Rik de Wijn 
(PamGene International B.V.) and author. 
 
A total of 67 patient samples were analyzed in 9 different units, and samples were applied 
blinded for TRG status. TRG 1-2 were defined as good responders, TRG 3 as intermediate 
responders and TRG 4-5 as poor responders. The samples were divided into two sets; a training 
set and a testing set. The training set consisted of 7 poor responders and 12 good responders, 
whereas the testing set consisted of the remaining patient samples.
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TRG/Plate Total Plate A Plate B Plate C Responder group 
TRG 1 5 0 3 2 
TRG 2 7 3 2 2 Good 
TRG 3 4 1 1 2 Intermediate 
TRG 4 7 4 1 2 
TRG 5 1 0 1 0 Poor 
Table 4. Distribution of 24 patients samples according to TRG in the three analyzed 
Pamchip®96 units used for the testing set. 
 
Peptides with generally low signal intensities were left out, leaving 86 of the initial 144 
peptides for further analysis. Before applying a classification method to high dimensional data, 
such as gene expression profiling or, as in our case, kinase arrays consisting of 86 peptides, 
dimension reduction is necessary. This is essential because most classification methods require 
the sample size (i.e. number of patients) to be larger than the number of variables. Dimension 
reduction basically aims to “summarize” the numerous predictors in form of a small number of 
new components before applying a classification method to the constructed components (175). 
Importantly, several complex methods for dimension reduction exist, and the below mentioned 
approach was chosen. 
 
Binary treatment response class prediction was performed applying partial-least-squares 
discriminant analysis (PLS-DA), and a leave-one-out cross-validation (LOOCV) was used to 
estimate the prediction performance in the training set. With LOOCV, one sample is left out 
and the remaining samples are used to build a classifier, which is then used to classify the left 
out sample. The fraction of samples that are classified correctly provides unbiased estimates of 
prediction error (71). Initially, all 8 poor responders were used in the training set, however, the 
single TRG 5 patient was classified as good responder, and to obtain a robust classifier we 
chose to exclude this sample from further analysis. Finally, a classification model based on the 
entire training set was built and used to predict response in the testing set. 
 
The large number of available biostatistical approaches for analyzing high dimensional data for 
predictive purposes indicates that there is no consensus as to which is the best method. This is 
an area of intensive research, and improvements can be expected in the future. Many models 
suffer from the risk of overfitting the data, meaning that the model classifies the training set 
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well, but future samples are classified poorly. However, the model used in this work is 
considered a relatively conservative strategy (176), and a reliable prediction can be expected 
given high sensitivity and specificity in an independent testing set. 
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6 Discussion 
 
6.1 Future treatment options in LARC 
 
New CRT regimens 
Combination of new chemotherapeutic drugs with today’s standardized 5-FU-based CRT is 
being extensively studied. In the majority of studies, the new combinatory regimens are derived 
from efficacy studies in metastatic colorectal cancer. Irinotecan was shown to improve outcome 
in metastatic colorectal cancer (177, 178), and in 2004, a randomized controlled trial confirmed 
that the combination of oxaliplatin and 5-FU was superior to the irinotecan/5-FU combination 
in this setting (179). Furthermore, inhibition of epidermal growth factor receptor (EGFR) and 
vascular endothelial growth factor (VEGF) has been shown beneficial in metastatic colorectal 
cancer (180-182). In clinical trials for rectal cancer, all these compounds have been 
incorporated as part of CRT regimens (183).  
 
New agents under clinical investigation in CRT for LARC are summarized below: 
• Irinotecan: Phase II trials have found a dose-dependent improved pCR rates (0-24%) 
with irinotecan implemented in CRT with acceptable toxicity (184, 185), and a German 
study found pCR of 15% (186). A recent phase III trial reported no improved efficacy 
and increased toxicity of irinotecan when implemented in postoperative CRT after a 3-
year follow-up (187).  
• Cetuximab: The inclusion of this EGFR-targeting antibody in preoperative CRT has 
been studied in several phase I or II trials, but with a somewhat disappointing low pCR 
rate of 8% in two of the conducted studies (188, 189). It has recently been suggested 
that a fraction of LARC tumors, those with wild-type K-ras and high EGFR gene copy 
number, may be sensitive to preoperative treatment with cetuximab (83). 
•  Gefitinib: This tyrosine kinase inhibitor, selective for EGFR, has been shown to be well 
tolerated when added to 5-FU based CRT in LARC and with a pCR rate of 30% (190).  
• Bevacizumab: Inhibition of VEGF signaling via this anti-VEGF antibody was shown in 
a phase I rectal cancer CRT study to have antivascular effects and encouraging tumor 
downstaging rates (191). Importantly, this antiangiogenic therapy in rectal cancer has 
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been associated with increased toxicity rates and higher than expected rates of colonic 
perforations (192). A phase III study randomizing to capecitabine and oxaliplatin with 
or without bevacuzimab is ongoing (193).  
• Celecoxib: This selective cyclooxygenase-2 inhibitor, which influences the 
prostaglandin synthesis, induced rash in 50% of LARC patients, and the trial thus was 
terminated (194). 
• Oxaliplatin: Several phase I and II studies, including the ongoing LARC-RRP study, 
have been conducted with oxaliplatin combined with 5-FU based CRT in LARC with 
relatively high pCR rates of 16-28% (183, 195-197). Randomized phase III trials are 
still recruiting patients (Table 5) (51, 198-200). 
 
Table 5. Ongoing phase III trials with or without oxaliplatin in neoadjuvant CRT in LARC 
Name of trial 
(country of origin) 
Study arms CRT (50 Gy in 2-
Gy fractions) 
Adjuvant 
chemotherapy 
PETACC-6 Arm A CAP CAP 
(Germany, Europe) Arm B CAP/OXA CAP/OXA 
CAO/ARO/AIO-04 Arm A 5-FU 5-FU 
(Germany) Arm B 5-FU/OXA 5-FU/OXA 
ACCORD 12/0405 Arm A CAP  
(France) Arm B CAP/OXA  
NSABP R-04 Arm A 5-FU  
(US) Arm B 5-FU/OXA  
 Arm C CAP  
 Arm D CAP/OXA  
Abbreviations: CAP – capecitabine, OXA – oxaliplatin. 
 
Chemotherapy without RT 
Neoadjuvant chemotherapy (NACT) refers to chemotherapy given without RT and before 
surgery, usually with full-dose combination regimens given before preoperative CRT, which is 
also the case in the LARC-RRP study, but chemotherapy may also be given postoperatively as 
adjuvant treatment. Since local recurrence rates have decreased to a level of 6-8% with new 
CRT regimens but without documented effect on metastatic spread and overall survival, NACT 
and adjuvant chemotherapy have been suggested to be the focus for the future direction in order 
to eradicate micrometastatic disease (201).  
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Chemotherapy may be an important intervention at an early stage of the disease, and at a stage 
where the patient is fit enough to tolerate full systemic doses of chemotherapy. It is also 
speculated whether NACT also induce shrinkage of primary tumor, thereby improving 
resectability and CRT response (202). For this reason the term “induction chemotherapy” has 
been proposed (17). However, NACT will delay both CRT and surgery, and in the case of 
cervical and head-and-nech cancer, NACT consistently failed to show any benefits in clinical 
trials (202). Phase II studies with NACT in rectal cancer have demonstrated promising results 
on local control, but effects on systemic disease have not been reported (196, 203). In ongoing 
phase III trials (Table 5), chemotherapy is administered postoperatively for a prolonged period 
of 4-5 months (198, 200). Currently, no evidence exists whether administration of postoperative 
chemotherapy in LARC patients with clear margins is beneficial (204). 
 
Non-surgical approach 
Since around 25% of LARC patients undergoing today’s neoadjuvant treatment end up with 
pCR (42), a strategy of close observation without immediate surgery has been suggested as an 
initial approach in a highly selected patient group with no detectable residual tumor after 
neoadjuvant treatment (72). A research group at the University of São Paulo School of 
Medicine conducted a trial that included patients with resectable distal rectal cancers (also T2 
tumors) to undergo neoadjuvant treatment and then omit surgery with excellent survival data 
(205). They further claimed that if failure after neoadjuvant treatment should be detected at a 
later stage, delayed surgery will be safe and will not influence survival (206). However, no 
reliable method for predicting pathological complete response exists, and the inclusion of low-
stage tumors might have affected the good survival rates in this study. A review concludes that 
this “wait-and-see” policy is insufficiently documented and should only be applied in patients 
who are recognized to be unfit for or refuse radical surgery (207). A prospective study with a 
non-operative approach is ongoing in the UK, and the patients enter a rigorous program of MRI 
and clinical and endoscopic follow-up, with urgent surgery if any evidence of recurrence is 
found (42). 
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Intraoperative radiotherapy (IORT) 
IORT allows high radiation doses to be applied locally to the tumor bed after resection while 
the dose-limiting structures are displaced during radiation exposure. IORT was used by our 
own institution until late 1990s, but was terminated because no definite effect of the treatment 
was seen (208). The treatment was also resource-demanding as the patients needed to be 
transported to the RT department under anesthesia during surgery. However, in recent years, 
different dedicated facilities have evolved, such as mobile IORT units that can be employed in 
any operating room without the need for specific shielding or room construction requirements. 
Even though no randomized trials have been performed, different reports are encouraging (209) 
and the technique may have a renaissance in the future.  
 
 
6.2 Oxaliplatin and SAHA as radiosensitizers in LARC 
In view of future treatment options, oxaliplatin and SAHA as potential new agents to be 
incorporated in preoperative CRT were evaluated in experimental colorectal carcinoma models 
in papers I and II. The role of the compounds as part of NACT or adjuvant chemotherapy was 
not assessed, as the main aim of chemotherapy given independently of RT is to eradicate 
micrometastatic disease, the so-called spatial cooperation effect, which can not be evaluated in 
the used model systems. Crucial for new compound to be integrated in CRT is the ability to 
potentiate the radiation effects in order to improve local control. 
 
Oxaliplatin 
As seen above, oxaliplatin is extensively being studied in clinical trials as potential candidate in 
preoperative CRT of LARC. However, scarce pre-clinical evidence of the potential benefits had 
been reported at the onset of these trials. In paper I, the combined oxaliplatin/radiation effects 
were evaluated in colorectal carcinoma cells and xenografts. 
 
In vitro clonogenicity demonstrated that oxaliplatin acted as radiosensitizer in colorectal 
carcinoma cells, and this was also shown in combination with 5-FU. It should be noted that the 
concentration range used (5-40 μM) is beyond a clinically obtainable concentration as a 2-hour 
iv injection of a normal patient dose (85 mg/m2) reaches a peak plasma concentration of 3.6 μM 
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(210). When adding oxaliplatin to fractionated RT and daily capecitabine in a colorectal 
carcinoma xenograft model, we could not detect an additional effect. This experiment harbored 
a couple of limitations worth to be mentioned: 
• All left-sided tumors were irradiated with the contralateral tumor as unirradiated 
controls. This approach reduced the number of mice that had to be used in the 
experiment. However, the unirradiated control tumors grew faster and we had to 
sacrifice the mice when the unirradiated tumors reached a critical size. Four of nine 
oxaliplatin/capecitabine/radiation-treated xenografts did not reach a 2-fold increase 
before the mice had to be killed. If allowed to grow further, a statistically improved 
effect in presence of oxaliplatin might have been found. 
• Two weekly cycles of oxaliplatin were given to the mice. In the LARC-RRP study, five 
cycles are given. Even if we could not detect any significant effect after two cycles in 
mice, more than two cycles might have caused significant radiosensitizing effects. 
However, mice would not tolerate such long-lasting treatment. 
• The dominating effect of radiation and capecitabine might have marginalized the 
contribution of oxaliplatin to the overall effect. 
• The oxaliplatin dose given to the mice might have been too low, however, the dose 
given was the maximum tolerated dose (211). The dose given to the mice (10 mg/kg) 
equals 35 mg/m2 (dose/body surface area) and a normal dose of oxaliplatin given 
concomitantly with radiation in humans is 50 mg/m2. 
• Adding a second model would have strengthened the evaluation of potential benefits of 
adding oxaliplatin in this setting. 
• Oxaliplatin was given iv 30 minutes before radiation exposure of practical reasons. The 
concentration of oxaliplatin has been found to be peaking 2 hours after ip injection in 
another xenograft model (212). 
 
Bearing these limitations in mind, as the only experimental model evaluating in vivo 
radiosensitizing effect of oxaliplatin in colorectal cancer, a conclusion that the integration of 
oxaliplatin into combined-modality treatment of rectal cancer is controversial can still be made. 
However, phase II trials, including the LARC-RRP study, report encouraging high pCR rates 
when oxaliplatin is implemented in preoperative CRT, but also higher toxicity rates, and results 
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from ongoing phase III trials will hopefully provide conclusive evidence. Preliminary results 
from two of these trials are expected in late June 2009. 
 
SAHA 
The exciting new group of compounds targeting histone acetylation, HDAC inhibitors, has 
demonstrated radiosensitizing properties. In paper II, SAHA was for the first time shown to be 
radiosensitizer in colorectal carcinoma cell lines as assessed by clonogenicity. Moreover, 
radiosensitization was observed in two colorectal carcinoma xenograft models.  
 
To elucidate whether the concentration/dose ranges used in the experiments are relevant, a 
comparison to humans can be made. After a normal dose of 400 mg SAHA (vorinostat) in a 
person, a peak plasma concentration of 1.8 μM after 1 ½ hours is reached (213). This dose 
equals 232 mg/m2 (dose/body surface area) in the author, whereas the dose of 100 mg/kg used 
in the mice experiments equals 357 mg/m2. Hence, the concentrations used in vitro (1 μM) and 
in vivo are for practical purposes within a relevant range. However, ip injection of SAHA 
causes higher bioavailability than oral intake of vorinostat, which is the normal administration 
route in humans. The dose of SAHA injected to the mice induced histone acetylation in the 
xenograft, which implies that a sufficient concentration was achieved within the tumor as 
regards the most evident biological effect. Similarly, in the PRAVO study, tumor biopsies have 
been sampled 3 hours after oral intake of 100, 200, 300 and 400 mg vorinostat, with histone 
acetylation demonstrated at all dose levels (compared to corresponding pre-treatment biopsies; 
data by our research group, not yet published). 
 
In conclusion, the results from the pre-clinical models render SAHA to be a promising 
candidate in preoperative treatment of LARC. For possible future integration into CRT, the 
effect of vorinostat must also be evaluated together with 5-FU or capecitabine. In vitro studies 
in colorectal carcinoma cell lines have demonstrated synergistic effect between 5-FU and 
SAHA when SAHA causes downregulation of thymidylate synthase (155). A recent phase I 
study has also shown that the combination of vorinostat with 5-FU and oxaliplatin (but without 
RT) is safe (214), and results from ongoing phase I trials will shortly provide results whether 
combination of vorinostat and RT is safe. Even though SAHA, with or without radiation, did 
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not show increased toxicity to the mice, it remains to be seen whether vorinostat increases 
normal tissue injury in humans as it apparently increases cancer cell radiosensitivity. Emerging 
data from the ongoing phase I PRAVO trial may turn out to be indicative in this regard. 
Preclinical experimental models evaluating combination of SAHA/5-FU/RT are also warranted. 
A new trial in preparation will study toxicity using preoperatively an HDAC inhibitor in 
combination with 5-FU in rectal cancer. If safe and indicative of being beneficial, efficacy 
studies may subsequently be undertaken. 
 
Histone acetylation as biomarker for radiosensitivity 
The assumption that histone hyperacetylation is a permissive requirement to obtain maximal 
combined HDAC-inhibitor/radiation effects was challenged in paper II. It has been suggested to 
use tumor histone acetylation, or mononuclear blood cell histone acetylation, as a biomarker to 
design in vivo antitumor protocols combining HDAC inhibitors and radiation. In the HCT116 
xenograft model, we demonstrated that the combined SAHA/radiation effect was significantly 
improved when radiation was applied at restored baseline levels of histone acetylation 
following SAHA injection compared to when xenografts were irradiated at maximum histone 
acetylation, whereas the SW620 xenograft model showed similar responses in these two 
situations. We can not comprehensively explain the difference between the two models; 
however, the models harbor well-characterized molecular differences such as in TP53 
mutational status. As the delayed increased radiosensitivity was observed in one of the two 
xenograft models only, a conclusion about optimal timing of radiation application following 
drug administration can not be made. Yet, the usefulness of histone acetylation as biomarker of 
HDAC-inhibitors in combination with radiation is debatable. The practical implication of this 
finding is that exact timing of vorinostat administration relative to radiation in a future clinical 
setting does not seem to be as important as previously believed.  
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6.3 The HDAC inhibitor TSA in HDAC2-mutated cell lines 
As detailed in the introduction, class I HDACs are ubiquitously expressed in tissues and are 
localized in the cell nucleus. The isoforms HDAC1, HDAC2, and HDAC3 have been 
investigated in colorectal cancer, and high expression is associated with aggressive tumors, low 
differentiation, and poor survival. In particular, HDAC2 has been shown to be an independent 
prognostic factor (215). 15-20% of colorectal tumors have microsatellite instability, causing 
HDAC2 inactivation mutation in 20-43% of these tumors (158, 216). 
 
In paper III, two versions of the RKO colorectal carcinoma cell line expressed HDAC2 whereas 
one cell line version did not. The most likely explanation is that a mutation has occurred during 
culturing to give rise to the HDAC2-defective subclone. This explanation has also been 
suggested by others (217). Loss of HDAC2 leads to resistance to HDAC inhibitor-induced 
apoptosis in cell lines, and it was suggested that loss of HDAC2 impaired cells’ ability to 
acetylate histones by TSA (158). In paper III , we demonstrated that histones are 
hyperacetylated following SAHA and TSA treatment regardless of HDAC2 mutational status, 
as has also been shown by others (216). Interestingly, cells cultured at high confluence, both 
HDAC2-defective RKO cells and wild-type HDAC2 HCT116 cells, have been shown to lose 
the ability to become hyperacetylated following TSA exposure (216). This may be the reason 
for the transient histone hyperacetylation seen in paper III, as cells grew more confluently 
during continuous exposure, and may also explain the findings by Ropero et al. It has also been 
shown that transient siRNA-mediated repression of HDAC2 induces HDAC1, and vice versa, 
and that deletion of HDAC1 or HDAC2 alone does not change the phenotype, whereas deletion 
of both induces a range of defects (217). These findings indicate an overlapping function 
between these two proteins, and since both enzymes acetylate histones, and both are inhibited 
by TSA, it is unlikely that histones are not acetylated following TSA exposure in HDAC2-
mutated cell lines. Our results confirm that both HDAC2-deficient and HDAC2-proficient RKO 
cells can be radiosensitized by TSA, and that HDAC2 status need not be taken into account 
when investigating HDAC inhibitors as radiosensitizers. 
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6.4 Prediction of CRT response in LARC by kinase activity profiling 
 
Background 
Protein kinases are enzymes that facilitate transfer of phosphate groups to amino acids upon 
activation, and may be tyrosine specific (tyrosine kinases) or threonine/serine specific. Protein 
kinase activation, and subsequent protein phosphorylation, is a key mechanism of information 
transfer in major signal transduction pathways relevant for cancer development (116, 218). 
Hence, targeting protein kinases with small-molecular inhibitors or antibodies that bind to and 
inactivate their function is an emerging therapeutic concept. More recently, the relevance of 
activated protein kinases in radioresistance and potential benefits of protein kinase inhibition in 
RT have been increasingly recognized (192, 219-222). One example is that increased tumor 
EGFR tyrosine kinase activity, or downstream signaling pathways, resulting in activation of the 
phosphateidylinositol-3-kinase (PI3-K)/protein kinase B (AKT), has been associated with 
radioresistance (219, 223). As proof of principle, Bonner et al. showed that cetuximab, which 
binds to the ligand-binding domain of EGFR, in combination with RT improved locoregional 
control and survival in advanced head-and-neck cancer compared to RT alone without 
increasing RT induced toxicity (224). In addition to theoretical considerations, these 
observations provide rationale for studying kinase activity profiling as a potential predictive 
marker of CRT response in LARC. The PamChip array technology is a novel platform that 
allows rapid, real-time measurements of phosphopeptide signatures generated by biological 
samples. PamGene International B.V. has two different microarray chips: one containing a 
panel of peptides with mainly serine/threonine phosphorylation sites, and one containing 
mainly tyrosine residues which was used in our studies (www.pamgene.com). 
 
Tyrosine Kinase PamChip® Array technology for prediction of CRT response 
In paper IV, pretreatment rectal cancer biopsies were analyzed for kinase activity, and we 
demonstrated that this technology may assist in predicting response to preoperative CRT. An 
accuracy rate of 95% in a subset of 7 poor responders and 12 good responders using LOOCV 
was detected, and furthermore, using a prediction model based on these 19 patients, an 85% 
accurate prediction was found in a testing set of 47 patients consisting of patients having 
intermediate or good pathological responses (TRG 1-3). This is comparable to what has been 
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found for gene expression analysis (71, 99-101) as prediction accuracies of 81%, 83%, 87%, 
and 89% by use of subsets of discriminating genes between responders and poor responders as 
assessed by tumor regression grade (TRG) or T-level downstaging was observed. Multiplex 
kinase activity is, therefore, a promising new tool in predicting response to preoperative 
chemoradiotherapy in rectal cancer. 
 
The procedure of collecting biopsies, tumor content validation, and analysis is somewhat labor-
demanding, but highly feasible. Patients have to undergo rectoscopy, but this is often performed 
as a standard procedure during pretreatment examinations. Other advantages are that the 
technology requires small volumes of tumor tissue. 
 
The main challenge in this study was the finding of very few poor responding patients, which 
challenged the statistical adaptation. We needed all poor-responding patient samples in building 
the prediction model, and the testing set consisted of intermediate or good responders only.  
 
For reasons detailed in the manuscript, a biological interpretation of the results is complicated. 
However, all peptides with discriminating signal intensities between poor and good responders 
showed that kinase activity in poor responders was relatively high. This is in agreement with 
the observation that kinase activation is associated with radioresistance.  
 
Perspectives 
Testing this technology in a larger scale is warranted to confirm the validity of the potential 
predictive tool; in particular, to validate prediction of poor responders. The variation between 
the PamChip®96 units necessitated normalization of the signal intensities in each Pamchip®96 
array. Good responders in each unit were used to normalize signal intensities, and for future 
experiments, a set of reference samples are needed to predict response in a set of patient 
samples with unknown response, unless another normalization method is developed. We also 
analyzed aliquoted lysates from HCT116 in each unit but normalization to these lysates did not 
reduce the inter-unit variation sufficiently. 
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This array technology may be extended by adding small-molecular tyrosine kinase inhibitors to 
the samples before analysis. This may have at least two potential advantages. First, it will 
provide us with tyrosine kinase inhibition profiles, which may correlate to radiation response. 
Secondly, inter-unit variation would probably be less for the inhibition profiles since peptide 
phosphorylation levels would be normalized against the corresponding baseline levels, which 
would be measured in the same unit. If this variation was negligible, good responder samples in 
each Pamchip®96 unit for normalization would not be needed. A pilot experiment has been 
performed to select promising inhibitors and to determine appropriate concentrations (Figure 
18).  
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Figure 18. Phosphorylation levels (i.e. signal intensity, log scale, Y axis) of 144 peptides 
following incubation with 7 small-molecular tyrosine kinase inhibitors (A-G) normalized to the 
phosphorylation levels of untreated lysate from a rectal cancer biopsy (DMSO). Experiments 
and figure made by Piet J. Boender (PamGene International B.V.) and author. 
 
The PamChip array technology may in the future also be developed to include more peptides, 
or a selected panel of relevant peptide substrates which may improve prediction of response. It 
should be noted that many new peptide array technologies are under investigation; however, 
paper IV is the first to evaluate this technology as a predictive tool in CRT response. 
 
To facilitate biological interpretation, validation with well-known methods such as 
immunoblotting using phosphospecific antibodies or antibodies to protein kinases for detection 
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of phosphorylation levels of analyzed proteins, or level of kinases in patient samples or 
xenografts could be performed. Immunohistochemistry may also be an option. Detection of 
phosphoproteins may also be measured by other high-throughput methods such as sandwich 
enzyme-linked immunosorbent assay, mass spectrometry analysis and reverse phase protein 
array (225-228). These methods are different from, but complementary to the PamChip array 
technology, and may in the future assist in validation of our findings. 
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7 Conclusions 
The search for new and more effective compounds to be integrated in preoperative CRT 
regimens in LARC has mainly taken place on the basis of drugs that have been shown to be 
efficacious in treatment of metastatic colorectal cancer. Such new agents should be rigorously 
tested in pre-clinical models, and should also be demonstrated to potentiate the effect of RT 
before being introduced in preoperative CRT for LARC. If the main objective of integrating a 
new drug is to kill micrometastatic cells or solely have a cytotoxic effect to the primary tumor 
(i.e. not enhance the effect of RT), the drug should be given in full-dose regimens independent 
of RT, either as NACT or as postoperative adjuvant treatment.  
 
Among the potential drugs to be integrated in CRT in LARC, oxaliplatin is considered 
promising and several phase III trials are ongoing. However, at the time oxaliplatin was 
introduced in clinical trials, scarce pre-clinical evidence was available demonstrating 
radiosensitizing effects of oxaliplatin in colorectal carcinoma cells. We showed that oxaliplatin 
was a radiosensitizer in colorectal carcinoma cell lines alone and in combination with 5-FU as 
measured by clonogenicity. However, oxaliplatin did not convincingly increase radiosensitivity 
when added to fractionated RT and capecitabine in a relevant mouse model. Even though only 
one in vivo model was tested and limitations exist for the experimental design, as the only in 
vivo data available, our results question the relevance of oxaliplatin as an in vivo 
radiosensitizer. Hence, the integration of oxaliplatin into combined-modality treatment of rectal 
cancer is still controversial.  
 
Several HDAC inhibitors have exhibited promising results in combination with RT in 
experimental models. SAHA, the only HDAC inhibitor approved by the US Food and Drug 
Administration for cancer treatment, performed convincingly as a radiosensitizer in in vitro and 
in vivo colorectal carcinoma models, rendering this drug as a potential promising supplement to 
current multimodal treatment strategies in rectal cancer. The current assumption that radiation 
must be applied at maximal histone hyperacetylation to obtain optimal effects was challenged, 
questioning the validity of using histone hyperacetylation as a molecular marker for 
radiosensitivity when combining HDAC inhibitors and RT. 
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Colorectal carcinoma cells with HDAC2 mutations were hypothesized to be partially resistant 
to histone acetylation by the HDAC inhibitor TSA, and based on this, HDAC2 status was 
suggested as a predictive marker of the effect of HDAC inhibitors. It was, however, 
demonstrated that histones were transiently acetylated by TSA irrespective of HDAC2 status. 
Furthermore, both HDAC2-deficient and HDAC2-expressing colorectal carcinoma cells were 
radiosensitized by TSA; hence, HDAC2 status needs not be taken into account when 
investigating HDAC inhibitors as radiosensitizers.  
 
The possibility of predicting response to preoperative CRT in LARC would be useful for 
stratifying poorly responding patients to alternative treatment schedules as well as sparing non-
responders from unnecessary treatment. CRT response was predicted with an accuracy of 85% 
based on multiplex kinase activity profiling performed on endoscopically acquired biopsy 
specimens. Because the number of patients, especially poor responders, was limited in the 
present study, larger prospective trials will be needed to confirm the validity of the present 
predictor. 
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